IL-12 induced modulation of tumor derived myeloid cell inflammatory responsiveness. by Mitchell, Courtney Jetun
University of Louisville
ThinkIR: The University of Louisville's Institutional Repository
Electronic Theses and Dissertations
8-2014
IL-12 induced modulation of tumor derived
myeloid cell inflammatory responsiveness.
Courtney Jetun Mitchell
University of Louisville
Follow this and additional works at: https://ir.library.louisville.edu/etd
Part of the Microbiology Commons
This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional
Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact
thinkir@louisville.edu.
Recommended Citation
Mitchell, Courtney Jetun, "IL-12 induced modulation of tumor derived myeloid cell inflammatory responsiveness." (2014). Electronic
Theses and Dissertations. Paper 991.
https://doi.org/10.18297/etd/991
   
 
IL-12 INDUCED MODULATION OF TUMOR DERIVED MYELOID CELL 
INFLAMMATORY RESPONSIVENESS 
  
By  
 
 
 
Courtney Jetun Mitchell 
B.S. Clark Atlanta University, 2007 
M.D. University of Louisville, 2014 
 
 
 
 
A Dissertation 
Submitted to the Faculty of the  
University of Louisville School of Medicine 
in Partial Fulfillment of the Requirements 
for the Degree of  
 
 
 
 
Doctor of Philosophy 
 
 
 
 
Department of Microbiology and Immunology 
University of Louisville 
Louisville, KY 
 
 
 
 
August, 2014 
 
 
Copyright 2014 by Courtney Jetun Mitchell 
 
All rights reserved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
IL-12 INDUCED MODULATION OF TUMOR DERIVED MYELOID CELL 
INFLAMMATORY RESPONSIVENESS 
  
By  
 
 
 
Courtney Jetun Mitchell 
B.S. Clark Atlanta University, 2007 
M.D. University of Louisville, 2014 
 
 
 
 
A Dissertation Approved on 
May 23, 2014 
 
 
 
by the following Dissertation Committee: 
 
 
_________________________________ 
Jill Suttles 
 
_________________________________ 
Haval Shirwan 
 
_________________________________ 
Nejat Egilmez 
 
_________________________________  
Jason Chesney 
 
 
 
iii 
 
DEDICATION 
 
Dedicated to my beloved mother, Jacqueline Marie Green (1964-2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
ACKNOWLEDGMENTS 
 
 Many have been instrumental in getting me to this point. First, I would like 
to thank the late Dr. Robert “Bob” Stout. Bob was such a great mentor. No matter 
what time of day or what else he had going on as chair of the department; he 
always had an open door for me. He was always ready to engage and discuss 
my next great idea, no matter how far-flung it might have been. He cared deeply 
about the students in the department, and supported me whole-heartedly during 
my project. Even at the close of his life, he was concerned with my path to 
getting my PhD. He challenged my thinking, and provided an example of strength 
under tremendous suffering. I will always be indebted to him for all he taught me 
and his unwavering support of all my research ambitions. Thank you Bob. I hope 
that this work is a reflection of the great man and scientist you were. 
 Dr. Jill Suttles, thank you for picking up the baton and stepping in to make 
sure I finished this part of my training. You have been an amazing woman of 
strength and resilience. I am proud to have worked for you and eternally grateful 
for the hand you had in my training. Literally, if it had not been for you, this 
project would not have been possible. Thanks for your patience, flexibility, and 
support. I owe my greatest appreciation to you for all you have done to help me. 
 I would like extend special thanks to the MD/PhD program for giving me 
the opportunity to pursue this path. Dr. Binks Wattenberg, thank you for seeing 
v 
 
something in me and allowing me to join the program. Victoria King, thank you for 
your support and encouragement during my 7 years here. Things would not have 
gone as smoothly as they have without you. 
 To my committee members, Dr. Haval Shirwan and Dr. Jason Chesney, 
thank you for you insightful suggestions and flexibility with committee meetings 
and my defense date. Dr. Nejat Egilmez, thank you for stepping in on such short 
notice to help me finish this final step. I really appreciate all of your help in this 
endeavor. 
 I have been extremely blessed to work with some amazing people while in 
the lab. Thank you, Kimberly Head for all your expertise and advice and for 
keeping the lab running like a machine. Thank you, Lihua Zhang for being my 
office buddy and western blot whisperer. Your skills were invaluable to this 
project, and I really appreciate you all’s help.  To Dr. Yangfang “Pei Pei”, Zhu, Dr. 
Kelly Casey Carroll, and Dr. Ashley Triplett, thank you all for being my sounding 
board in the lab. Thank you all for listening to me laugh, sing, and cry. You all 
made hard days in the lab a little easier. I am extraordinarily lucky to have found 
friends like you all. To Dr. Katharine Richardson, thanks for showing me the 
ropes when I first started in the lab.  To the other current and former lab 
members, Shunmugavadiv “Meena” Vanchinathan, Bing Li, Jonathan Brown, 
Christina Akimana, Tad Dryden, Carolyn Roberson, thank you for making the 
Suttles/Stout lab a pleasant place to work.  
 To my husband, Marion Mitchell, thank you for being a patient and 
supportive partner. You have encouraged me every step of the way. When I felt 
vi 
 
like giving up, you were the one who told me that I could do it. Thank you for 
helping me care for my brother and for being a generous and unselfish person. 
Without you, I would not have made it. I am appreciative of everything you have 
done to help me and I love you dearly.  
To my Louisville medical school friends, Dr. Heather Lee, Jayci Roney, 
Esq., Dr. Suma Chennubhotla, Dr. Sally Diebold, Dr. Nichole Sonderman, Dr. 
Beth Dicken Todd, and Dr. Aman Ghotra, you all are amazing. I love each and 
every one of you. You have made my time spent in the Louisville the best. You 
were right there to through this whole process and always knew how to make me 
feel good about myself. Thanks for being awesome friends. 
 To my mother, thank you for believing in me and telling me I could do 
whatever I dreamed. Thank you for giving me my carefree spirit and loving me 
unconditionally. I think of you every day and I miss you terribly. 
 To all my friends and family in Itta Bena, Mississippi, Chicago, Illinois, 
Birmingham, Alabama, and everywhere in between  (who are too numerous to 
list individually) thanks for all the love and support. I am so lucky to have such a 
rock solid support system. You all have had a tremendous part in my success. To 
my brother, Couric Green, thank you for helping me become a responsible adult.  
I am proud of the man you are becoming. I hope that you will continue to push for 
excellence in all aspects of your life. You all are my inspiration and motivation. 
 Thanks to the University of Louisville School of Medicine, Department of 
Microbiology and Immunology for being a nurturing and supportive place to learn 
and grow. 
vii 
 
Thanks to the National Institutes of Health, National Cancer Institute, Ruth 
Kirchstein Predoctoral Fellowship F31 Award, MD/PhD program, Susan G. 
Komen, and Jennie C Benedict Scholarship for providing financial support during 
my training. 
Finally, I praise God for his continued blessings and the opportunities He 
has allowed in my life.  
viii 
 
ABSTRACT 
 
IL-12 INDUCED MODULATION OF TUMOR DERIVED MYELOID CELL 
INFLAMMATORY RESPONSIVENESS 
 
Courtney Jetun Mitchell 
 
May 23, 2014 
 
Tumor infiltrating and tumor associated myeloid cells (TIMs and TAMs) elaborate 
an array of factors that promote tumor growth and metastasis. IL-12, a potent 
inflammatory cytokine has been shown to induce regression of many cancers. 
We hypothesize that IL-12 augments the ability of TIMs and TAMs to respond to 
inflammatory stimuli providing a window in which these stimuli are more likely to 
promote tumor destruction. Related to this hypothesis, we asked two questions: 
(1) Does IL-12 directly change signaling events associated with inflammatory 
signal transduction? (2) Is IFNγ required for the entirety of IL-12 induced 
enhancement of the response of TIMs to inflammatory stimuli? First, we looked 
broadly at the in vivo effects of microspheres containing IL-12 on the growth and 
metastasis of 4T1 tumors. We also did studies with tumor cell-dendritic cell fusion 
for future examination of the impact of IL-12 and myeloid cells on the efficacy of 
tumor cell-dendritic cell fusion vaccines in mice. Most of this dissertation
ix 
 
focuses on in vitro work using TIMs and TAMs isolated from wild-type BALB/c or 
IFNγ deficient mice bearing the 4T1 mammary carcinoma. TIMs and TAMs were 
pretreated in vitro with IL-12 followed by LPS. TNF, IL-6, and IL-10 cytokine and 
mRNA levels were measured. We also examined the impact of IL-12 on the 
response 4T1 TIMs to tumor derived products. The phosphorylation of a number 
molecules involved in inflammatory signaling pathways, including MAPK proteins, 
were assessed by Western Blot.  We found that treatment of TIMs with IL-12 
followed by exposure to LPS enhances the amount of IL-6 and TNF with a 
reciprocal decrease in IL-10. This observation is associated with increases in the 
phosphorylation of MAPKs. The presence of IFNγ is only partially necessary for 
these effects. We observed that IL-12 only significantly impacted the production 
of IL-10 from 4T1 TAMs in response to LPS. IL-12 caused a significant increase 
in the amount of TNFα and IL-6 in response to tumor derived products without 
affecting IL-10. Our results provide additional insight into direct changes induced 
by IL-12 to the functional phenotype of TIMs and TAMs in response to 
inflammatory stimuli.  
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CHAPTER I 
 
INTRODUCTION 
 
 
Myeloid Derived Cell Phenotypic and Functional Diversity 
 
Myeloid derived cells are heterogeneous innate immune cells from the 
myeloid lineage of bone marrow-derived hematopoietic stem cell precursors. 
These cells include monocytes, macrophages, neutrophils, dendritic cells, and 
myeloid derived suppressor cells. Macrophages are phagocytic cells broadly 
distributed in tissues within the body, and are mature forms of circulating blood 
monocytes (1).  These cells are critical for innate immune responses and assist 
in priming the adaptive immune system to attack pathological insults (1). 
Macrophages are remarkably dynamic and display an array of functions 
and activities. In addition to their phagocytic properties, macrophages are 
capable of presenting antigen to adaptive immune cells, secreting factors 
important for wound healing, and establishing the extracellular matrix (1).  
Interestingly, many macrophage functions are in direct opposition to one another. 
Inflammation provides an excellent illustration of the diverse functions of 
macrophages. In the formative stages of inflammation, macrophages secrete 
pro-inflammatory cytokines, chemokines as well as cytotoxic factors that activate 
surrounding immune and stromal cells, attract auxiliary innate immune cells and 
specialized adaptive immune cells. All of these functions work
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together to initiate the killing or clearance of the offending inflammatory agent (2, 
3).  As inflammation progresses, macrophages secrete less pro-inflammatory 
cytokines and begin to elaborate factors that aid in the resolution of inflammation, 
wound healing, and angiogenesis (2, 3). 
As evidence of the spectrum of functions macrophages may exhibit, 
several subsets of macrophages have been described in the literature. 
Discussions continue as to whether these subsets are distinct lineages of 
myeloid cells locked into a particular functional state or transient cellular 
phenotypes that change given the stimulus or the environment (2-5). A simplistic 
classification of macrophages based on T-helper cell categorization was 
introduced by Mills, labeling macrophages as either M1 or classically activated 
and M2 or alternatively activated (6). Macrophage secretion of pro-inflammatory 
cytokines, such as TNF-alpha (TNF), IL-1 beta (IL-1), IL-12, IL-6, IL-15, 
metalloproteinases (MMPs) and nitric oxide, and expression of pro-inflammatory 
genes, such as iNOS and co-stimulatory molecules B7 and major 
histocompatability class II molecules (MHC II) in response to IFN gamma (IFNγ) 
followed by LPS treatment, generally characterize classically activated 
macrophages (7, 8). Conversely, macrophages exposed to IL-13 in combination 
with IL-4 display the alternative activated phenotype characterized by the 
secretion of anti-inflammatory cytokines like IL-10, transforming growth factor-
beta (TGF), vascular endothelial growth factor (VEGF) and the expression of 
anti-inflammatory genes including, arginase I and mannose receptor I (9).  
Attempts to incorporate the complex and diverse functional phenotypes of 
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macrophages have been made by the use of sub-classifications of the original 
M1-M2 paradigm (7) or a color wheel for macrophage classification based on the 
functional environment, the major examples being immune regulation, wound 
healing, and host defense (3, 10, 11). Overall, macrophages are remarkably 
diverse cells that display a plethora of functional phenotypes under the influence 
of various environmental factors. 
 
Macrophage Activation and Counter-Regulation 
Activation 
Macrophages can be induced to display various functional phenotypes by 
many activating agents. Upon encountering various signals in the environment, 
macrophages can be activated to secrete cytokines and mediators of 
inflammation, present antigens for adaptive immune cell activation, and kill 
intracellular and extracellular bacteria. Specific examples of macrophage 
activators include bacterial lipopolysaccharide (LPS), CD40 ligand (CD40L or 
CD154), and IFNγ.   
The activation of macrophages via LPS has been extensively studied. 
Macrophage stimulation with LPS leads to a variety of effector functions through 
the integration of many complex intracellular signaling pathways. LPS is a 
component of the outer membrane of gram-negative bacteria (12). LPS acts as 
an endotoxin and binds to the pattern recognition receptor (PRR), toll-like 
receptor 4 (TLR4) and co-receptors CD14 and MD-2 on macrophages (13-15). 
Intracellular signals from the LPS/TLR4/MD-2 complex are transmitted via 
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adaptor proteins, myeloid differentiation factor 88 (MyD88) or TIR-containing 
adaptor molecule (TRIF) (16). Early TLR4 signaling via the MyD88 pathway is 
responsible for elaborating most of the pro-inflammatory cytokines classically 
associated with LPS activation of macrophages (17). The MyD88 pathway leads 
to the degradation of inhibitors of kappa beta (IκΒs), which allows for the 
activation and nuclear translocation of NF-κB (18). NF-κB is a protein complex 
consisting of dimers of any of its 5 family members that include p65, p50, Rel, A, 
Rel B, and c-Rel (19). The dimerization of the p65 and p50 subunits is associated 
with LPS stimulation (20). The delayed MyD88 independent, TRIF-biased 
pathway signals through tumor necrosis factor receptor-associated factor (TRAF) 
family member associated NF-κB-activator binding kinase (TBK1) to activate IFN 
response factor 3 (IRF3) (21-23). This leads to the release of type I interferons 
such as interferon Β (IFNβ) (21). The TRIF-biased pathway can also lead to the 
delayed activation of NF-κB (23)  
The CD40 signaling pathway in macrophages has also been thoroughly 
investigated (24).   CD40 is a member of the tumor necrosis factor receptor 
(TNFR) family (25, 26). This co-stimulatory molecule is found on the surface of 
macrophages, B-cells, T cells, dendritic cells, and endothelial cells (27-30). 
Engagement of CD40 on macrophages, by its ligand, CD154 leads to secretion 
of pro-inflammatory cytokines and elaboration of reactive oxygen species (31-
33).  CD154 is a member of the TNF family of proteins (34). It can be found 
bound to the cell surface of various immune cells or in a soluble form (34). 
Introduction of CD154 in tumor bearing mice has been shown to decrease the 
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number of suppressive myeloid cells and increase T cell activation(34). Signaling 
events downstream of CD40 include the phosphorylation of protein tyrosine 
kinases (PTKs), such as Janus activated kinase 3 (JAK3) (35), which can lead to 
the activation of transcription factor signal transducer and activator of 
transcription 3 (STAT3) and STAT6 (35, 36).  CD40 ligation has been shown to 
lead to activation of   serine/threonine kinases: c-jun amino-terminal 
kinase/stress activated protein kinase (JNK/SAPK), p38 mitogen-activated 
protein kinase (MAPK), and extracellular signal-regulated mitogen-activated 
kinase (ERK)(37, 38).  Activation of CD40 by CD154 also enlists tumor necrosis 
factor receptor-associated factors (TRAFs) to transmit signaling cascades to 
downstream transcriptional mediators (39). TRAF2, TRAF3, TRAF5, and TRAF6 
have shown to play a role in CD40 signaling (40). CD40 signaling can result in 
the activation of NF-κB via TRAF2 and TRAF6, and the activator protein 1 (AP-
1), and nuclear factor of activated T cells (NF-AT), all of which can mediate 
inflammatory cytokine production (40-43).  
 
Another example of a macrophage activator is IFNγ. IFNγ is the sole 
member of the type II interferon group (44). Th1 lymphocytes, NK cells, and 
macrophages produce IFNγ, which is a potent endogenous activator of 
macrophages (45-48). Genes that are upregulated in macrophages in response 
to IFNγ include MHC class I and II, anti-viral proteins, inflammatory cytokines and 
chemokines (46, 49).  IFNγ binds to its receptor to form a heterodimer of type II 
cytokine receptors, interferon gamma receptor gamma 1 and 2 (IFNGR1 and 2) 
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that leads to the activation of JAK1 and JAK2 that subsequently phosphorylate 
IFNGR1 (50, 51).  This phosphorylation event provides a docking site for STAT1 
(50-52). STAT1 phosphorylation allows it to dimerize and translocate into the 
nucleus to bind to target genes on interferon response elements (52, 53). IFNγ 
has been shown to prime macrophages to be tumoricidal and for subsequent 
stimulation by activating stimuli such as LPS (54-56).   Overall, macrophages are 
activated by a variety of stimuli that integrate numerous signaling pathways 
leading to diverse functional phenotypes. 
  
Counter-Regulation 
Of equal importance to macrophage activation is macrophage counter-
regulation. Excessive inflammation can cause tissue damage and pathology. 
Thus, the dampening and resolution of macrophage inflammatory activities are 
very important.  The immune system has evolved to include several mechanisms 
to negatively regulate inflammation. Macrophage activation can be attenuated in 
several ways.   
In addition to the pro-inflammatory cytokines secreted by macrophages in 
response to LPS, concurrent signaling events lead to the elaboration of IL-10, a 
potent anti-inflammatory cytokine.  Twenty years ago, it was first demonstrated 
that IL-10 was produced by human monocytes in response to LPS (57). The 
same study showed that IL-10 inhibited the release of IL-1α and β, IL-6, TNFα, 
and IL-8 in response to LPS and/or IFNγ (57).  Subsequent reports have 
unmasked a complex network of activators and signaling components that 
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regulate IL-10 expression in macrophages and mediate its downstream anti-
inflammatory effects.  Several transcriptional factors have been implicated in the 
regulation of IL-10 in macrophages. These include specificity factor (Sp) 
activators, STATs, c-Musculoaponeurotic Fibrosarcoma (c-MAF), activator 
proteins (AP-1), CCAAT/Enhancer binding proteins (C/EBP), and cAMP 
response element binding protein (CREB) (58). Sp1 binds to the G-rich portion of 
the IL-10 promoter (59, 60). Lack of endogenous Sp protein leads to complete 
ablation of IL-10 promoter activity (59). STAT1 and STAT3 recruitment to the IL-
10 promoter has been demonstrated, although evidence of direct binding of 
STAT proteins to existing cis-elements within the IL-10 promoter is not available 
(61, 62). In macrophages, the protoonocogene, c-MAF, a member of the basic 
leucine zipper family of transcription factors is constitutively present and is 
ushered to the IL-10 promoter upon TLR ligation in response to LPS (63). 
C/EBPs can act as homo- and heterodimers in TLR-dependent and independent 
pathways to impact IL-10 gene expression (58). In response to LPS, C/EBP 
proteins synergize with Sp1 to enhance IL-10 transcription (64). Alternatively, 
cAMP stimulation through the adenosine receptor can lead to activation of the IL-
10 promoter in a MyD88-independent mechanism via C/EBP (65).  MyD88-
independent activation of the IL-10 promoter may also be due to CREB activation 
(66). In response to cAMP stimulation, CREB is phosphorylated and 
accompanied into the nucleus with its co-activators, histone acetyl transferases, 
CREB binding protein (CBP) and p300(67, 68). This leads to hyperacetylation of 
histones at the IL-10 promoter and ultimately, increased transcription of IL-10 
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(69).  Phosphorylation of serine 10 on histone H3 is thought to be a critical 
epigenetic marker for transcriptional activation of the IL-10 gene (69) 
IL-10 binds to its receptor, IL-10 receptor (IL-10R), a tetramer consisting of 
two heterodimers of the two subunits, IL-10R1 and IL-10R2 (70). Upon ligation, 
IL-10R1 associates with JAK1 that is then phosphorylated (71). JAK1 
phosphorylation and activation leads to the phosphorylation of STAT3, an 
indispensible mediator of IL-10 anti-inflammatory function (71). STAT3 enters the 
nucleus and facilitates the transcription of several anti-inflammatory genes 
including ETS family transcriptional repressor, ETV3, a helicase family co-
repressor, Strawberry notch homologue 2 (SBNO2), and suppressor of cytokine 
signaling 3 (SOCS3) (72). SOCS3 is part of an 8-member family of proteins 
characterized by a Src homology 2 (SH2) domain, a variable N-terminus and a 
conserved region termed the SOCS box at its C-terminus. Two members of this 
group, including SOCS3 have a kinase inhibitory region (KIR) at the N-
terminal(73).   SOCS3 binds phosphorylated tyrosines on cytokine receptors, 
especially the IL-6 receptor component gp130, to inhibit signal transduction. 
SOCS3 is thought to be key molecule in distinguishing between IL-10 and IL-6 
cellular signaling (74, 75). Although both IL-6 and IL-10 induce STAT3 and 
SOCS3, SOCS3 selective inhibition of the IL-6 receptor component, gp130, 
disallows IL-6 from displaying anti-inflammatory characteristics associated with 
IL-10 (74, 75). A STAT3 independent pathway for IL-10 gene expression has 
been elucidated that includes phosphatidylinositol 3’ kinase (PI3K), glycogen 
synthase kinase 3 beta (GSK3β), and Akt, which controls IL-10 induced 
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expression of autotaxin, Egr2, caspase5, and signaling lymphatic activation 
molecule (SLAM) (76). 
Because persistent high levels of IL-10 lead to immunosuppression and 
render the host susceptible to pathogenic insult, negative regulation of IL-10 is of 
vital importance. IL-10 induced SOCS3 can inhibit STAT3 activity creating a 
negative autoregulatory loop (75). Additionally, MHC class II transactivator 
(CIITA), and poly (ADP) ribose polymerase 1 (PARP-1) (in an allelic specific 
manner) have been shown to negatively regulate IL-10 expression in innate 
immune cells (77, 78).  Interestingly, studies have demonstrated that IFNγ can 
inhibit IL-10 production in response to LPS (79, 80).  It was shown that IFNγ 
inhbits IL-10 through diminishing the effects of the MAPK pathway, and the 
PI3K/Akt/GSK3b pathways (80).   
 
The MAPK signaling pathway 
Optimal intracellular communication in macrophages and other immune 
cells requires a complex system of highly integrated and tightly controlled 
signals. Various signaling pathways must converge upon numerous transcription 
factors and ultimately genes to regulate the function of macrophages. These 
same pathways may exert post-transcriptional and post-translational 
modifications to further dictate the macrophage functional phenotype, adding 
another layer of complexity to the signaling tableau.  The MAPK pathway is an 
example of a single signaling pathway that can influence a broad spectrum of 
other signaling pathways. This pathway has been shown to be involved in a wide 
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variety of signaling cascades that control myeloid cell response to inflammatory 
stimuli.    The expansive influence of the MAPK pathway on the macrophage 
functional phenotype is evident as this pathway modulates and contributes to the 
propagation of signals transmitted by LPS, IFNγ, and CD40.  
MAPKs are family of proteins that form a tiered system for relaying signals within 
cells (81). In response to a stimulus, MAPK kinase kinases (MAP3Ks) are 
activated.  These activated MAP3Ks go on to activate MAPK kinases (MAP2Ks 
or MEKs) via phosphorylation of specific serine and threonine residues. Finally, 
MAP2Ks proceed to activate MAPK family members, ERKs, p38s, and JNKs, 
through phosphorylation of specific tyrosines and threonines. Once activated 
MAPKs can bind and activate various transcription factors and enhancers to 
regulate gene transcription (81).  
The first MAPKs discovered were ERK family members including ERK1, 
ERK2, MAPK1, and MAPK3 (82). ERK family members are encoded by two 
genes, ERK1 and ERK2 and require dual phosphorylation at Thr203 and Tyr205 
(ERK1) and Thr185 and Tyr187 (ERK2) for activation (82). ERKs can be 
activated by a well-defined pathway initiated by the Ras protooncogene, or via 
Ras-independent pro-inflammatory stimuli such as TNFα and LPS (83).  
JNKs were first described as protein kinases found in the livers of 
cycloheximide treated rats (83). Like ERKs, JNKs have a variety of activators. 
JNKs are extremely sensitive to mitogens, environmental stressors like heat 
shock and ionizing radiation, pro-inflammatory cytokines, endoplasmic reticular 
(ER) stress, DAMPs, and PAMPs (81). There are 3 JNK family members, JNK1-3 
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(81). Genes of the same name encode them, with each family member having 
several isoforms as a result of alternative splicing. JNKs are dually 
phosphorylated at Thr 183 and Tyr185 (82). A large number of MAP3Ks have 
been shown to lead to the activation of JNKs including MEKK1, MEKK2, MLK1, 
MLK2, and MLK4 (84). These MAP3Ks lead to the phosphorylation of two 
MAP2Ks, MKK4 and MKK7. Both MKK4 and MKK7 are required for JNK 
phosphorylation (85, 86).  A well-known substrate for JNKs is AP-1. 
A third MAPK family member is p38.  There are four p38 genes and 
identically named proteins: p38 (MAPK14), p38 (MAPK11), p38 (MAPK12), 
and p38 (MAPK13) (83). The p38 and p38 isoforms are ubiquitously 
expressed, while the other isoforms are distributed with more tissue specificity 
(82).  Most literature refers to p38 because it is the most abundant of the two 
ubiquitous forms. Like the two previously mentioned MAPKs, p38 is activated by 
a wide variety of PAMPs, DAMPs, pro-inflammatory cytokines, and 
environmental stressors. Activation of p38 requires phosphorylation at Thr180 
and Tyr182 (82). 
Given the wide distribution and extensive activating signals of the MAPKs, 
it is not unexpected that it has been shown that these proteins are critical to the 
macrophage’s response to stimuli. In response to LPS TLR4 ligation, ERK1/2, 
JNK, and p38 are all activated by both the early MyD88 dependent pathways and 
late MyD88 independent, TRIF dependent routes (82). LPS triggers the activation 
of the MAP3K, tumor locus progression 2 (Tpl2 aka Cot3 and MAP3K8). Tpl2 
activates MKK1 (MAP2K1) and MKK2 (MAP2K2) (87). This leads to ERK1/2 
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activation (87). This pathway has been shown to be crucial and required for LPS 
induced TNFα and prostaglandin E2 (PGE2) secretion (87-89). 
Of the three MAPK family members, p38 has been demonstrated to be the 
most critical MAPK mediator of LPS provoked gene transcription (90). Illustrating 
the importance of p38 in the inflammatory phenotype of macrophages, 
conditional deletion of p38 in macrophages significantly decreased the 
secretion of pro-inflammatory cytokines, TNFα, IL-12, and IL-18 in response to 
LPS in vitro, and diminished sepsis in two in vivo animal models (91). This is 
apparently due to the extreme reduction in activation of CREB and CEB/P when 
p38-/- macrophages are exposed to LPS (91).  It is thought the MAPK activated 
protein kinase 2 (MK2) is the downstream target of p38 that controls CREB 
activation (92). This pathway is also important for IL-10 and COX2 production 
(92). 
The MAPK family proteins are also implicated in the IFNγ signaling 
pathway. Like LPS, IFNγ induces p38, ERK1/2, and JNK (93, 94). It was shown 
that p38 is involved with controlling the level of expression of genes required for 
the innate immune response, including CCL5, CXCL9, and CXCL10; cytokines 
such as TNF-α; and inducible NO synthase (iNOS). Alternatively, JNK-1 was 
shown to affect genes involved in antigen presentation like CIITA and MHC class 
II molecules (93). 
  
Myeloid Cells and Cancer 
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As demonstrated by the intricate integration of multiple signaling 
pathways, understanding the continuously changing macrophage and other 
myeloid cells functional phenotype under normal physiological conditions is a 
complex proposition alone.   In a diverse and complicated pathological condition 
such as cancer, deciphering the function and role of macrophages and myeloid 
cells presents a unique challenge. The idea of inflammation being connected with 
the initiation of cancer can be traced back to Virchow’s 1863 observation of the 
“lymphoreticular infiltrate” in cancer and his postulation that cancer may arise at 
sites of chronic inflammation (95). Conversely, the importance of the immune 
system in defending against cancer has also been appreciated. Activation of the 
immune system with “Coley’s Toxin,” a mixture of attenuated bacterial products, 
was shown to induce the regression of osteosarcoma (96). Later studies have 
shown that immunization of mice with irradiated tumor cells prevents the growth 
of the same viable tumor cells but not different, unrelated, viable tumor cells (97). 
The evidence supporting the influence of the immune system has on initiation, 
growth, spread, and eradication of cancer prompted Weinberg et al., to list 
“avoiding immune destruction” and “tumor promoting inflammation” as emerging 
hallmarks in his latest update of the highly cited Hallmarks of Cancer: The Next 
Generation (98, 99).   
Macrophages and other myeloid-derived cells have been shown to be 
critical for several aspects of tumor initiation, progression, and metastasis. 
Several groups have shown that the presence of high numbers of myeloid cells 
within tumors is associated with a poor prognosis in many cancers (100-103).   
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Chemically induced, obesity-driven and virus-mediated cancer models provide 
clear links between inflammation and cancer initiation.  A report showing that the 
anti-inflammatory protein SOCS3 decreases dextran sodium sulfate (DSS) and 
azoxymethane (AOM) associated tumorigenesis in the gut highlights the role of 
inflammation in chemically induced cancers (104). A recent study showed that 
human adipose tissue macrophages (ATMs) induced lipid accumulation and an 
inflammatory phenotype in human cancer cell lines (105). Additionally, these 
ATMs displayed genes associated with cancer related pathways and were 
genetically similar to TAMs (105). Macrophages were also found to be 
associated with malignant transformation of the human papilloma virus-infected 
cervix (106). Once tumors are established, macrophages and other myeloid cells 
including myeloid-derived suppressor cells (MDSCs) display an 
immunosuppressive, anti-inflammatory phenotype that assists tumor cells in 
evading immune detection. MDSCs are a heterogeneous subset of immature 
myeloid cells that can be grouped as either granulocytic (CD11b+, Ly6G+) or 
monocytic (CD11b+, Ly6C+) (107-109). It is reasonable to speculate that these 
cells are a product of the remarkable plasticity of macrophages and myeloid cells 
and the ability of macrophages to respond to various environmental factors (2).  
C-C chemokine receptor 2+ (CCR2+), CD11b+ monocytic MDSCs were shown to 
aid in tumor immune escape by limiting the infiltration of activated T cells into the 
tumor (110).  One study revealed that TAMs in renal cell carcinoma secrete high 
amounts of chemokine (C-C) ligand 2 (CCL2) and IL-10 that contribute to 
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immunosuppression and perpetuate the recruitment and maintenance of more 
TAMs (111).  
The Pollard et al., was one of the first to definitively show that 
macrophages were vital for cancer metastatic progression when they 
demonstrated that mice lacking macrophage colony stimulating factor-1 (CSF-1) 
did not have changes in tumor incidence or growth, but had delayed 
development of invasive, metastatic cancers (112). This study highlighted one of 
the most critical roles macrophages perform over the course of a cancer. The 
ability of macrophages to promote tumor invasiveness and metastasis through 
modulating stromal elements and supporting abnormal vascularization and 
angiogenesis has subsequently been thoroughly researched. Hypoxia within the 
tumor microenvironment causes TAMs to secrete VEGF that supports immature 
blood vessel formation leading to vascular leakiness, which promotes cancer 
metastasis (113). A study identified a subset of TAMs that express the 
angiopoietin receptor, TIE2 that is critical for macrophage induced angiogenesis 
(114).   Also important for tumor spread is degradation of the surrounding stroma 
and extracellular matrix. Macrophages have been shown to secrete high 
amounts of MMPs that can degrade tissue and allow metastasis (115, 116). 
  
In addition to tumor infiltrating myeloid cells and macrophages found 
within the tumor that work to suppress the immune system and aid in tumor 
escape from the original site, several studies have shown that TAMs away from 
the primary tumor work to prime distal locations for cancer metastasis.  It has 
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been demonstrated that macrophages are essential for metastasis and growth of 
tumor cells at distant sites (112). Additionally, it has been illustrated that 
macrophages in the lung are key in initial stages of cancer cell seeding and 
extavasation (117). Qian et al., demonstrated that distal tissue stromal cells and 
early metastatic cancer cells secrete CCL2 that attracts inflammatory monocytes 
and macrophages (118). This study showed that these macrophages promote 
the extravasation and growth of tumor cells at distant sites, in part, via the 
secretion of VEGF (118). Additionally, it was recently reported that tissue factor 
mediated coagulation helped recruit macrophages to pre-metastatic niches and 
this recruitment is necessary for metastatic cancer cell survival (119).  It has also 
been shown that macrophages support tumor cell survival at distal sites by 
expressing α4-integrin on their surface which binds to cancer cell expressed 
vascular cell adhesion molecule 1 (VCAM-1) (116). This α4-integrin-VCAM-1 
interaction leads to the activation of pro-survival signals in the cancer cells via 
the phosphoinositide 3-kinase (PI3K)/AKT pathway (116). 
The dichotomous role of macrophages and myeloid cells in cancer, with 
their ability to initiate and promote tumor growth, while suppressing their own 
capability to thwart cancer progression, provide an opportunity for targeting these 
cells in anti-cancer therapies.   
 
Myeloid Cells and Immunotherapy 
Current Immunotherapeutic Approaches and Challenges 
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In addition to the traditional therapeutic approaches to cancer including 
chemotherapy, radiation therapy, and surgery, immunotherapy has reemerged as 
a viable component of a successful cancer treatment plan. The recent FDA 
approval of Sipuleucel-T (Provenge), an autologous immunotherapeutic, 
illustrates the potential impact of thoughtful and effective immunotherapeutic 
agents (120, 121).  Sipuleucel-T treatment requires that a patient’s peripheral 
mononucluear blood cells (PMBC) be removed and exposed to a fusion protein 
consisting of prostatic acid phosphatase (PAP) and the cytokine, GM-CSF (120, 
121). This treatment results in both clinical and statistical improvement of 
prostate cancer patient outcomes (120, 121). Another instance in which the 
effectiveness of immunotherapy is evident is in the use of Ipilimumab (Yervoy), a 
human monoclonal antibody that antagonizes a negative regulator of cytotoxic T 
cells, cytotoxic T-lymphocyte antigen 4 (CTLA-4), to render cytotoxic T cells more 
active against melanoma (122, 123).  
It is generally accepted that a major difficulty in cancer immunotherapy is 
the robust immunosuppressive environment established in part by myeloid cells. 
An approach to alleviating this profound immunosuppression is the exploitation of 
the functional plasticity of myeloid cells. As demonstrated by earlier cited 
literature, macrophages and other myeloid cells have the remarkable ability to 
respond to environmental signals including the tumor microenvironment. The 
strategy of altering the phenotype of macrophages from a tumor and metastasis-
supportive, immunosuppressive phenotype to an anti-tumorigenic, pro-
inflammatory phenotype would provide an avenue to activate the immune system 
18 
 
to eradicate cancers. One such agent that has been shown to have anti-tumor 
effects and changes the functional profile of macrophages is the cytokine IL-12.   
 
The Biology of IL-12 
Michiko Kobayashi and Giorgio Trinchieri first described IL-12 in 1989 as 
NK cell stimulatory factor (NKSF) (124). IL-12 is a heterodimeric cytokine 
composed of two disulfide-linked subunits, p35 and p40 that together form the 
p70 unit (125, 126). The p35 subunit shares homology with other cytokines such 
as granulocyte colony stimulating factor (G-CSF) and IL-6, while the p40 heavy 
chain is shared with IL-23 and is a member of the hemapoietin receptor family 
along with ciliary neurotrophic factor (CNTF) and the IL-6 receptor (127). IL-
12p40 can be secreted as a monomer or a homodimer and is thought to have 
antagonistic activity, while IL-12p35 is not found in a monomeric form (128).  The 
genes for the IL-12 subunits are located on separate chromosomes. In humans 
p35 is on chromosome 3 and p40 is on chromosome 5, while in mice p35 and 
p40 are on chromosomes 6 and 11, respectively (125).   IL-12 is secreted by a 
variety of immune cells including monocytes and macrophages, neutrophils, 
dendritic cells, and B cells (129). IL-12 can initiate pro-inflammatory functions in 
NK cells, T cells, and myeloid cells, making it an attractive, multivalent agent to 
reverse the strongly immunosuppressive tumor microenvironment (129). IL-12 is 
a strong inducer of IFNγ from T cells, NK cells, and myeloid cells; it also induces 
immune cell proliferation, and enhances cell-mediated toxicity (129).  
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The IL-12p40 gene is regulated at the transcriptional level (130). The p40 
gene can be induced by a variety of microbial products. The p40 promoter has 
been shown to have binding sites for several transcription factors including NF-
κB, IRF-1, c-Rel, interferon consensus binding protein, and Ets family members 
(130-134). Deletion of the cis-elements at the Ets or NF-κB binding site restricts 
p40 promoter activity (135).  Conversely to p40, p35 is ubiquitously expressed 
and controlled both transcriptionally and translationally (136).   Although there is 
constitutive synthesis of the p35 message in unstimulated cells, scant protein is 
actually produced due to an inhibitory ATG sequence at the 5’ untranslated 
region (136). When a stimulus is applied to cells, the transcriptional start site is 
altered, and the inhibitory region is not included in the message (136).    
Many DAMPs and PAMPs can prompt IL-12 production. They include 
LPS, Lipoteichoic acid (LTA), peptidoglycan, and bacterial (CpG) DNA, and they 
work independent of T cells (137, 138). IL-12 is also made in response to antigen 
presenting cell CD40 ligation by CD40L on T cells (139). A positive feedback 
loop is established when IL-12 induced IFNγ triggers more IL-12 production in a 
macrophage cell line (131, 140). Alternatively, IL-12 synthesis is attenuated by 
IL-10, IL-11, IL-13, and type I IFNs (141-143). It has also been demonstrated in 
macrophages that stimulation of G-coupled protein receptors (GCPRs) including 
the receptors for MCP-1, prostaglandin E2, histamine, and Fc receptor activation 
can inhibit IL-12 production (144-147). Interestingly, cholera toxin, an activator of   
a GPCR subunit, and the measles virus via CD46 inhibit IL-12 production (148-
151). 
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IL-12 binds to it receptor, IL-12 receptor (IL-12R)(152). The IL-12R 
consists of 2 chains, 1 and 2 (152). They are members of the type I cytokine 
receptor family with close homology to IL-6 receptor component, gp130 (127).  
The human IL-121 and IL-122 genes are found on chromosomes 19 and 1 in 
humans and on chromosomes 8 and 6 in mice, respectively.  The IL-12 receptor 
is expressed on NK cells, T cells, dendritic cells, and macrophages. Co-
expression of both chains confers optimal responsiveness to IL-12 although the 
2-subunit is often used to predict IL-12 activity due to the presence of three 
cytoplasmic tyrosine residues on the 2-chain (127, 153). 
The IL-12 signal is transmitted from the IL-12R via the JAK-STAT pathway 
(127). The 1-receptor chain interacts with JAK2 while the 2-receptor subunit 
associates with the tyrosine kinase, TYK2 (154, 155). The previously mentioned 
tyrosine residues on the 2-receptor are phosphorylated upon IL-12 ligation, 
which allows for the recruitment, phosphorylation, and activation of STAT4. 
Although it has also been reported that STAT1 and STAT3 are activated by IL-
12, STAT4 is thought to be the major component of the IL-12 signaling pathway 
as STAT4 deficient mice display an identical phenotype to IL-12p40 deficient 
mice (156, 157). STAT4 binds to both the human and murine Ifng gene (157-
159). IL-12 stimulation also results in the phosphorylation of Src family tyrosine 
kinase, Lck and the MAPK, p38 (160-162). Activation of p38 by IL-12 appears to 
be important for IFNγ production and Th1 differentiation (162). STAT4 has been 
shown to be negatively regulated by the ubiquitin E3 ligase, SLIM (163).  
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Much of IL-12’s physiological influence has been attributed to its activation 
of adaptive components of the immune system and NK cells and its elicitation of 
IFNγ.  IL-12 can directly induce the proliferation of pre-activated T and NK cells 
and augment the proliferation of resting and naïve cells caused by several 
mitogenic agents (153, 164). IL-12 can also enhance the generation of cytotoxic 
T lymphocytes (CTL), NK and lymphokine activated (LAK) cells by eliciting the 
transcription of genes such as those for granzymes, peforin, and adhesion 
molecules that render these cells more cytotoxic (164). One of the essential roles 
of IL-12 is the induction of IFNγ secretion by T cells, B cells, and NK cells (153, 
165).  IL-12 alone, or in synergy with IL-18, a member of the IL-1 cytokine family 
can cause IFNγ secretion (166-168). The IL-12-IFNγ axis in conjunction with 
signaling through the T cell receptor (TCR) and other receptors is crucial for Th1 
differentiation (153).   
 
IL-12 and Myeloid Cells 
More attention has been placed on how IL-12 may be involved with other 
immune cells including myeloid cells. Most of this work has focused on the 
autocrine effects of IFNγ from IL-12 stimulated macrophages. Macrophages have 
been shown to produce nitric oxide and upregulate surface molecules associated 
with antigen presentation in response to IL-12 (169). Both of these effects are 
dependent on IFNγ as this phenotype is erased in IFNγ-/- mice (165, 170). 
Additionally, IL-12 has been demonstrated to prime macrophages to produce 
copious amounts of NO in response to LPS and IFNγ (171). Some work also 
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suggests that IL-12 may regulate TGF-1 production since macrophages from 
mice deficient in p40 chain of IL-12 secrete high amounts of TGF-1 (172). 
 
IL-12 as a Cancer Immunotherapeutic   
Because IL-12 can activate both the innate and adaptive arms of the 
immune system, much effort has been used to investigate its effectiveness as an 
anti-tumor agent and therapeutic vaccine adjuvant.  Initial studies in several 
animal models of cancer yielded promising results regarding IL-12 alone or in 
combination with other cytokines as an immunotherapeutic drug and vaccine 
adjuvant. IL-12 has been shown to be very effective in eradicating tumors in 
mouse models of breast cancer, melanoma, thymoma, renal cell carcinoma, 
colon cancer, and lung cancer (173-178). However, early clinical trials with IL-12 
were unsuccessful, largely due to the profound cytotoxicity associated with 
systemic administration of IL-12 (179). Researchers continue to work to find safe 
alternatives for administering IL-12 in humans. There are currently several active 
clinical trials involving IL-12 and various cancers. These phase I and phase II 
clinical trials include IL-12 in combination with a dendritic cell breast cancer 
fusion vaccine (NCT00622401), the heavy chain of the antibody of NHS576 
which targets double-stranded and single-stranded DNA that are exposed in 
areas of necrosis (NCT01417546), a plasmid DNA vaccine for Merkel cell cancer 
(NCT0144081816), the monoclonal antibodies cetuximab and daclizumab 
(NCT01468896 and NCT01307618), and T cells engineered to secrete IL-12 in 
metastatic melanoma (NCT012365718) (clinicaltrials.gov). Most of IL-12’s in vivo 
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anti-tumor effect has been attributed to CD8+ and CD4+ T cells, as well as NK 
cells. It has also been reported that IL-12 can activate NKp46+ lymphoid tissue-
inducer cells (LTi cells) to induce tumor rejection (177). Recently the impact of IL-
12 on TAMs has been studied. Our lab showed that IL-12 modified the functional 
phenotype of TAMs in vivo and in vitro and that TAMs released cytoplasmic IL-15 
in response to IL-12 in vivo, and that this event was critical for the initiation of IL-
12’s anti-tumor activity (173, 180). It was more recently shown that IL-12 
enhances the ability of myeloid cells within tumors to improve the activation and 
cytotoxicity of CD8+ T cells (175).  
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Rationale, Significance, and Hypothesis 
Our attention to the relationship between IL-12 and tumor associated 
macrophages an myeloid cells is well-founded given the accumulating evidence 
showing myeloid cells as remarkably plastic, the significant influence these cells 
have on cancer growth, metastasis, and immunosuppression, and the use of IL-
12 as an anti-cancer therapy. Understanding the impact of IL-12 on TIMs and 
TAMs is an important component in deciphering the mechanisms related to IL-12 
immunotherapeutic effects. 
Recent work has identified TIMs and TAMs as direct targets of IL-12 
(175). What is not completely clear is how IL-12 affects the function of 
macrophages especially independent of IFNγ. We hypothesize that IL-12 
augments the ability of TIMs and TAMs to respond to inflammatory stimuli 
providing a window in which these stimuli are more likely to promote tumor 
destruction. Related to this hypothesis we wanted to investigate whether IL-12 
changes signaling events associated with inflammatory signal transduction and 
determine if IFNγ required for all of the IL-12 induced changes in the response of 
TIMs and TAMs to inflammatory stimuli. 
Herein, we use the highly aggressive and metastatic 4T1 mammary 
carcinoma murine model to look at the impact of IL-12 on the growth 4T1 tumors 
as well as isolate myeloid cells and study their in vitro response to LPS 
stimulation as well as tumor derived factors after exposure to exogenous, 
recombinant IL-12. We also examined the impact of pre-incubation of TIMs with 
IL-12 followed by LPS treatment on MAPK pathway signaling. Finally, we sought 
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to determine if IFNγ was compulsory for the increased inflammatory profile and 
increased MAPK phosphorylation in TIMs exposed to IL-12 followed by LPS. 
  This work provides insight into role of IL-12 in the context of IFNγ and the 
MAPK pathway, both of which have broad influence in immunology and cancer.  
This study offers a corollary to the classically identified mechanisms of IL-12 in 
innate immunity and cancer immunotherapy. 
 
 
*Note: In this dissertation, TIMs refers to tumor infiltrating myeloid cells and 
TAMs refers to tumor associated myeloid cells. Previous works refer to TIMs and 
TAMs as tumor infiltrating macrophages and tumor associated macrophages.  
We designated TIMs as being directly from within the tumor while TAMs are from 
distal sites of a tumor bearing mice. Some studies do not make this distinction 
and use TAMs designation for any macrophage or myeloid cell from within the 
tumor as well as other tissue sites in a tumor bearing animal. We use the 
designation of myeloid cells because portions of  the pooled CD11b+ cells used 
in experiments displayed markers for macrophages (F4/80+) or MDSCs (Gr1+). 
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CHAPTER II 
 
IL.12 REDUCES THE IN VIVO GROWTH OF THE 4T1 MAMMARY 
CARCINOMA 
 
 
Introduction 
Breast cancer is the most common cancer diagnosis and the second most 
common cause of cancer deaths among women in the United States (181). The 
incidence of breast cancer rose from 1973-1990, but then began to decline, while 
mortality from breast cancer remained steady until recently as annual decreases 
in mortality have been observed (181). In spite of these statistics, it is well known 
that breast cancer prognosis is bleak and mortality increases when metastases 
are present, an indication of late-stage disease (182). The 5-year survival rate for 
stage IV breast cancer is only 15% (182). The poor clinical outcomes that 
accompany late-stage breast cancer provide an impetus to identify new and 
effective treatment strategies, especially ones that focus on disrupting 
immunosuppression and inhibiting metastatic processes associated with breast 
cancer. 
In this chapter, we observed the growth of the 4T1 mammary carcinoma in 
syngeneic BALB/c mice and measured the impact of IL-12 microspheres on 
tumor progression. Fred Miller and colleagues first isolated the spontaneously 
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occurring mouse 4T1 mammary carcinoma (183). It reliably metastasizes to lung, 
liver, and brains when implanted (183).  
As previously stated, initial cancer clinical trials in human using IL-12 were 
unsuccessful due in large part to systemic cytotoxicity and short half-life of free 
cytokine (184). In our in vivo experiments, we use recombinant IL-12 
encapsulated in polylactic acid to facilitate slow, sustained release of IL-12, and 
to circumvent IL-12-associated cytotoxcity.   
Prior studies in our laboratory have demonstrated that IL-12 has a 
profound impact on tumor associated macrophages in the Lewis lung carcinoma 
(LLC) mouse model (180). Therefore we sought to expand our understanding of 
IL-12’s impact on TIMs and TAMs in a breast cancer cell line. Because the 4T1 
cell line is a syngeneic mice model with consistent metastasis, it is a good 
system to monitor the role of macrophages in both early stages of tumor initiation 
as well later metastatic events.  Additionally, this model is an excellent platform 
to study agents such as IL-12 that modulate the immune system with regards to 
the tumor microenvironment. 
There is current interest in developing therapeutic cancer vaccine as 
opposed to prophylactic vaccine such as those associated with preventing 
human papilloma virus (HPV), which subsequently prevents cervical carcinoma. 
One approach to developing therapeutic vaccines is the fusion of dendritic cells 
and tumor cells. Dendritic cells are innate immune cells that are the primary 
antigen-presenting cells (APCs) within the immune system. Fusion of dendritc 
cells and tumor cells allows for combination of antigen presentation machinery, 
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such as CD80, CD86, and MHC molecules, and tumor-associated, and tumor-
specific antigen (185). This fusion optimizes tumor antigen presentation through 
both the class I and II MHC pathways to generate potent immune responses from 
adaptive immune cells, such as CD8+ and CD4+ T cells (185).  Clinical trials 
using patient bone marrow-derived dendritic cells and autologous cancer cells 
have been successful in treating cancers (186-188). This aim looks to confirm the 
anti-tumor effects of IL-12 in the 4T1 breast cancer model, as well begin to 
understand if and how IL-12 may impact the efficacy of a dendritic cell fusion 
vaccine. 
  
 
Methods and Materials 
  
Mice and cell lines 
Seven to eight week old female BALB/c mice were obtained from Jackson 
Laboratories. All animal care was in compliance with relevant protocols, 
guidelines, and regulations approved by the University of Louisville Institutional 
Animal Care and Use Committee.  4T1 cells were obtained from ATCC. Tumor 
cells were maintained through in vivo passage with limited intermittent in vitro 
culture. 
  
In vivo tumor injections 
BALB/c mice were injected subcutaneously near the left, rear mammary 
fat pad with 2x104 4T1 cells. Tumors were measured at 3-day intervals with 
calipers at two bisecting diameters. An approximate volume was calculated using 
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the formula (Length*Width2)*6/. Tumor weights were also measured upon 
harvest.  
 
IL-12 treatment 
Microspheres containing 250ng/mg of IL-12 or empty control microspheres 
were prepared by phase inversion nanoencapsulation and were supplied by Dr. 
Nejat Egilmez (University of Louisville School of Medicine).  Microspheres were 
resuspended at 2mg/100L in sterile phosphate buffered saline (PBS). At the 
indicated time point, mice received one intratumoral injection of 4mg of IL-12 or 
control microspheres. 
 
Lung harvest and staining 
The lungs of 4T1-bearing BALB/c mice were perfused with 30mL of 
Dulbecco’s PBS (Cellgro) supplemented with 2% fetal bovine serum (FBS) 
(Atlanta Biologicals) using a 30mL syringe and a 20G1/2 needle. Lungs were 
placed in Omnisette tissue cassettes (Fisher Scientific), and the cassettes were 
submerged in 10% formalin solution, neutral buffered (Sigma) for 24 hours. Lung 
containing cassettes were then added to 70% ethanol for further processing. 
Lungs were paraffin-embedded and sections were stained with Hematoxylin 
Eosin (Embedding and staining performed by the University of Louisville Special 
Procedures Laboratory). 
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Bone marrow derived dendritic  cells (BMDCs) cell generation 
The femurs and tibias of BALB/c mice were flushed with DPBS+2%FBS 
using a 1mL syringe and 26Ga needle. Cells were passed through a nylon filter 
(Bellco), and red blood cells were lysed using Gey’s solution. Cell were plated in 
100mm dishes in RPMI 1640 (Hyclone) containing, 5% FBS, 1M HEPES 
(Sigma), 10mg/mL Gentamicin sulfate (Sigma), 20ng/mL GM-CSF (R&D 
Systems), and 1:100 Glutamax (Invitrogen) for 7 days at 370C. Media was 
refreshed at days 2 and 5. 
   
4T1 and BMDCs fusion and selection 
4T1 tumor cells and BMDCs were mixed at a ratio of 1:5 in FBS-free RPMI 
1640 containing 1M HEPES and 10mg/mL Gentamicin sulfate and polyethylene 
glycol (PEG) (Sigma Hybrimax) at 370C. CD11c positive cells were selected 
using EasySep mouse CD11c+ selection kit and magnet (StemCell 
Technologies). Cells were plated for 1 week and loosely adherent fused cells 
collected for further use. 
 
Flow cytometry 
Cells were stained with 1ug/106 cells anti-CD32/CD16 Fc block (BD 
Pharmingen). Cells were then stained with 0.2ug/uL anti-CD326 APC 
(eBioscience), rat anti-IgG PE (BD Pharmigen) and rat anti-IgG2a APC 
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(eBioscience). Acquisitions were performed using FACScaliber (BD Biosciences) 
and analysis was done using Flowjo (Tree Star). 
 
Statistics  
Significant differences between groups were determined using 2-tailed 
student’s T test. 
 
Results  
In vivo administration of IL-12 microspheres diminishes 4T1 growth and 
lung metastasis 
We aimed to validate that microspheres loaded with recombinant IL-12 
reduced in vivo tumor growth and metastasis in the 4T1 model of breast cancer.  
Our results demonstrate that a single intratumoral injection of IL-12 microspheres 
precipitated significant decreases in tumor growth. Injection of IL-12 
microspheres at day 12 resulted in a significant decrease in tumor weights 
(Figure 1).  The growth curve of tumors injected with IL-12 microspheres at day 5 
was significantly altered with IL-12 treated tumors showing a decreased rate of 
expansion (Figure 2).  We were also interested in validating the impact of IL-12 
on 4T1 tumor metastasis.  We observed that injection of IL-12 microspheres at 
day 9 had a substantial effect on tumor metastasis as lungs from 4T1-bearing 
animals had diminished metastasis when compared to controls (Figure 3).  
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Polyethylene glycol facilitates 4T1 and dendritic cell fusion 
Additionally, we sought to fuse 4T1 cell and dendritic cells to investigate 
how IL-12 affects the efficacy of a fusion vaccine. Our long-term interests include 
investigating whether IL-12 induced changes in the macrophages contribute to 
enhancing the efficacy of a tumor dendritic cell vaccine. Initial attempts at 4T1 
and dendritic cells fusion using polyethylene glycol (PEG) were successful. We 
were able to facilitate approximately 27% fusion of CD11c+ dendritic cells with 
4T1 cells as indicated by cells double positive for the epithelial marker, CD326 
and CD11c (Figure 4).   
Discussion 
Results in this aim demonstrate that in vivo treatment with IL-12 reduces 
both 4T1 growth and metastasis. Also, our data illustrates that exposing 4T1 and 
dendritic cells to PEG is a reasonable method to facilitate adequate fusion of 
these cells for eventual use as a tumor vaccine in mice. One of the drawbacks of 
IL-12 cytokine therapy is its transient effect when used as a singular treatment 
(189, 190). Subsequent studies to understand the mechanisms by which IL-12 
exerts it effects on TIMs and TAMs will assist in prolonging and exploiting the 
positive effects of IL-12.  It is important that the window of decreased 
immunosuppression initiated by IL-12 be used to introduce anti-cancer 
treatments such as therapeutic vaccines.  
TIMS and TAMs are clear mediators of the profound immunosuppression 
within the tumor microenvironment. Studies directly linking role of TIMS and 
TAMs in cancer immunosuppression and obstacles to effective cancer 
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therapeutic vaccination are important to expanding the number effective 
immunotherapeutic options available. Studies have shown that depletion of TIMs 
and TAMs improved the effects of chemotherapeutic agents (191-193), but little 
data exist directly showing that changing the functional profile of myeloid cells 
within the tumor microenvironment is sufficient and/or necessary to positively 
impact the efficacy of chemotherapeutic agents or therapeutic vaccines. Work in 
this aim is a precursor for future studies that will investigate the potential roles of 
TIMs, TAMs, and IL-12  in establishing long-term cancer remission in response to 
therapeutic vaccination.  Our future goals include ascertaining the in vivo 
duration of the change in myeloid cell function after exposure to IL-12. We would 
also like to examine whether IL-12 prompted myeloid cell conversion to a pro-
inflammatory, anti-tumorigenic phenotype will improve the efficacy of a dendritic 
cell-based vaccine.  
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Figure 1 
 
 
Figure 1. In vivo IL-12 administration decreases 4T1 tumor weights. BALB/c 
mice were challenged with 2x104 4T1 cells. At day 12, mice were treated 
intratumorally with 4mg of control microspheres or microspheres containing 
1000ng of rmIL-12. At day 26, tumors were resected and weighed. The average 
tumor weights were determined. n=7 for untreated group, n=8 for control group, 
n=7 for IL-12 group. *p<0.05 for untreated vs. IL-12 and control vs. IL-12. Error 
bars=SEM 
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Figure 2 
 
Figure 2. In vivo IL-12 administration decreases the rate of 4T1 tumor 
growth. BALB/c mice were challenged with 2x104 4T1 cells. At day 5, mice were 
treated intratumorally with 4mg of microspheres containing 1000ng of rmIL-12 or 
1000ng of blank microspheres as a control group. At set intervals, tumors were 
measured manually with calipers. Tumor volume was determined using the 
formula (L*W2)*6/. Average tumor volume was calculated for each day. n=5 for 
control and IL-12 groups. p value<0.05 for difference between groups at day 14, 
17, and 19. Error bars=SEM 
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Figure 3 
 
  
Figure 3. In vivo IL-12 administration decreases 4T1 tumor metastasis. 
BALB/c mice were challenged with 2x104 4T1 cells. At day 9, mice were treated 
intratumorally with 4mg control microspheres or microspheres containing 
1000mg of rmIL-12 or left untreated as a control group. Lungs were harvested at 
day 26. H&E staining was performed and lung metastasis visually observed. 
Results are representative images of 5 lungs per treatment group. 
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Figure 4 
 
 
Figure 4. Polyethylene glycol 
(PEG) facilitates fusion of 4T1 
tumor cells and bone marrow-
derived dendritic cells. Bone 
marrow derived dendritic cells 
were fused with 4T1 tumor cells 
at a ratio of 1:5 (4T1:DC) using 
50% PEG. Fused CD11c+ cells 
were positively selected. A.) 
Epithelial cell marker, CD326, 
but not dendritic cell marker, 
CD11c, is expressed on 4T1 
cells. B.) CD11c, but not CD326 
is expressed on dendritic cells. 
C.) CD11c+/CD326+ cells after 
fusion (upper right quadrant). 
Data is representative of 2 
independent experiments.
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CHAPTER III 
IL.12 MODIFIES RESPONSE OF TUMOR ASSOCIATED AND TUMOR 
INFILTRATING MYELOID CELLS TO LPS VIA IFNγ INDEPENDENT AND 
DEPENDENT MECHANISMS   
 
Introduction 
The functional profile of macrophages and myeloid cells within tumors is 
an important determinant of the immune system’s ability to defend against the 
growth and spread of the tumor. A plethora of research has shown that 
macrophages play a multi-faceted role in the initiation and progression of 
cancers. Research has expanded our understanding of the link between 
inflammation and cancer. This new knowledge has evolved into a model that 
describes cancer-related inflammation through the intrinsic or extrinsic pathways 
(5, 194). The intrinsic pathway refers to changes in oncogenes and tumor 
suppressor genes that contribute to initiation of inflammation (195). Alterations in 
genes such as RET, RAS, and MYC lead to the elaboration of pro-inflammatory 
cytokines and growth factors (5). These cytokines and growth factors activate 
immune cells including macrophages within the vicinity, which perpetuates the 
inflammatory state and can eventually lead to tumor formation (5). Conversely, 
the extrinsic pathway describes external factors such as chronic infection or 
chemical and environmental exposures that promote inflammation (195). Chronic 
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 infection increasing the risk for cervical cancer (194) or ultraviolet radiation 
associated inflammation ultimately progressing to skin cancer are examples of 
the extrinsic pathway of cancer related inflammation. The intrinsic and extrinsic 
pathways both lead to the activation of transcription factors such as NF-κB and 
STAT3 (194, 195)  Macrophages and myeloid cells are critical in these formative 
steps in cancer related inflammation. Macrophages within this inflammatory 
milieu produce TNF, IL-6, COX2, reactive nitrogen and oxygen species that 
have been shown to promote cancer formation in a number of ways.  Reactive 
nitrogen and oxygen species promote cancer formation by inducing mutagenesis 
and genetic instability by disrupting the activity of p53 and enhancing the activity 
of DNA methytransferases, which leads to errant transcription (196, 197).  IL-6 
and TNF promote carcinogenesis by stimulating angiogenesis and cell 
proliferation (198).   
Inflammation is tightly control process that integrates various signals that 
initially promote, but eventually down-regulate inflammatory mediators. In cancer-
related inflammation, homeostatic controls are still present although they are 
likely deranged. Changes in the functional phenotype of the macrophage and 
myeloid derived cells are integral in the shift towards immunosuppression in the 
tumor microenvironment (199). After chronic inflammation has persisted and 
cancer has been established, signaling pathways in macrophages and myeloid 
cells are activated that aid in thwarting the activities of immunocompetent cells 
which allows for tumor cell evasion and escape.  A recent report showed that the 
non-canonical Wnt protein, Wnt5a induces a tolerogenic phenotype in TAMs 
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through a negative feedback loop with NF-κB (200). This study also reported that 
Wnt5a leads to the accumulation of immunosuppressive macrophages in breast 
cancer patients (200).   Others have shown that perturbations in NF-κB signaling 
such as the formation of non-canonical p50 homodimers may be pivotal in the 
macrophages immunosuppressive phenotype specifically via increased IL-10 
secretion (201, 202).  
It has been shown that TIMs from a mouse sarcoma produced significantly 
less pro-inflammatory IL-6, TNF, and IL-1 and more anti-inflammatory 
cytokines IL-10 and TGF and IFN-inducible chemokines MCP1, CCL5, CXCL9, 
CXCL10, and CXCL16 than thioglycollate-elicited peritoneal macrophages in 
response to LPS (203). This observation is attributed to defective MyD88 
activation of NF-κB, but intact stimulation of the MyD88-independent IRF3 and 
STAT1 signaling pathway in TAMs and TIMS (203). More recent studies suggest 
that TLR4 stimulation of TAMs results in enhanced ERK1/2 phoshorylation that 
induces IRAK-M expression, a known inhibitor of MyD88 (204).  
The association between the presence of large tumor infiltrates of 
macrophages and myeloid cells and poor patient prognosis for several different 
cancers is widely recognized (100-102, 205).  This observation initially prompted 
research that looked to eradicate macrophages and myeloid cells within the 
tumor environment to improve outcomes in cancer patients (191) (206). 
Additionally, reports showed that macrophages within the tumor 
microenvironment displayed the “M2” phenotype that is immunosuppressive and 
tumor supportive (199, 207). This information further promoted the view that 
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macrophage eradication was a plausible approach to alter the microenvironment 
and positively impact patient outcomes. Clodronate, a bisphosphonate initially 
used to decrease hypercalcemia in multiple myeloma patients, was adapted for 
use to systemically eliminate myeloid cells and macrophages. Although this 
approach yields reduced cancer immunosuppression, the use of clodronate is 
limited by its systemic toxicity (207). This approach also fails to appreciate the 
plastic nature of macrophages and myeloid cells and their pro-inflammatory 
potential. So rather than removing macrophages from the tumor 
microenvironment completely, efforts to understand how to exploit the 
manipulability of macrophages may be more suitable to cancer 
immunotherapeutic endeavors (4).  
Our lab is interested in the impact of IL-12 on macrophages and myeloid 
cells within the tumor microenvironment. We propose that IL-12 facilitates the 
opening of an pro-immunological window in TIMS and TAMs which deems them 
more permissive to subsequent inflammatory stimuli. We have previously 
demonstrated that polarized TAMs and TIMs can be converted from 
immunosuppressive and tumor-supportive to pro-inflammatory and immunogenic 
in vivo and in vitro which may contribute to tumor eradication after exposure to 
IL-12 (180). In addition, work in this laboratory showed that in vivo introduction of 
IL-12 in tumor-bearing mice leads to rapid release of IL-15 for TIMs which is 
critical for cancer regression and is not dependent on the presence of NK cells 
(173). Others revealed that IL-12 enhances the ability of myeloid cells within the 
tumors to activate CD8+ T cell cytotoxicity (175). These reports demonstrate IL-
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12 as a modulator of the functional phenotype of macrophages and myeloid cells 
in the tumor microenvironment.  
  The relationship between IL-12 and IFNγ is well established as 
previously discussed in the first chapter of this dissertation.  IL-12 induction of 
IFNγ from NK cells, macrophages, and T cells is pivotal to adaptive immune 
responses (208).  Studies have shown that IFNγ is very important in IL-12 
induced changes in macrophages and IL-12’s overall anti-tumorigenic effects 
(175, 209). For example a study showed that IL-12 induced IFNγ caused cell 
cycle arrest T-regulatory cells and enhanced tumor clearance (210). Less 
research has focused on any IFNγ independent IL-12 effects on macrophages 
and myeloid cells in the tumor microenvironment. In a series of experiments, 
Kerkar et al., showed that although IFNγ was required for IL-12 induced tumor 
regression, the host’s endogenous cells (immune cells included) ability to 
respond to IFNγ was only partially required (175).  This report showed that when 
wild-type (WT) and IFNγ-/- CD8+ T cells transduced with melanoma antigen, p-
mel TCR, and IL-12 were adoptively transferred into WT mice bearing B16 
melanoma tumors, both the WT and IFNγ-/- p-mel/IL-12 T cells induced a similar 
degree of tumor regression. Conversely, in the IFNγ-/- mice bearing B16 
melanoma, anti-tumor responses were significantly impaired with both WT and 
IFNγ-/- p-mel/IL-12 T cells. This showed that IL-12 induced IFNγ from 
endogenous cells in the tumor microenvironment was required to elicit anti-tumor 
response. Interestingly, when IFNgr-/- mice bearing B16 melanoma were injected 
with WT p-mel/IL-12 T cells there was only a partial reduction in IL-12 anti-tumor 
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effects. This suggests that although IFNγ production by endogenous cells is 
required for IL-12’s anti-tumor effects, the endogenous cell (including immune 
cells) response to IFNγ is not the sole determinant of IL-12 induced tumor 
regression. This data presents the possibility that IL-12 effects on endogenous 
cells including immune cells that are independent of IFNγ as well as IFNγ’s direct 
interaction with tumor cells may also be components of IL-12 anti-tumor 
mechanisms. 
Although research has thoroughly investigated many components of the 
IL-12 signaling pathway such as JAK2, TYK2, and STAT4, not as much focus 
has been placed on other downstream mediators of IL-12 signaling, especially in 
the context of myeloid-derived cells. As discussed in the dissertation’s 
introduction, there are many signaling elements that play a role in determining 
how myeloid cells respond to inflammatory stimuli. These include NF-κβ, WNT, 
AKT, AMPK, and SOCS among others. One pathway that has been explored in 
the context of IL-12, but deserves more attention because of its broad influence 
over inflammatory pathways is the MAPK pathway. Most of the published data 
concerning IL-12 and the MAPK pathway addresses the pathway’s involvement 
in IL-12 synthesis in response inflammatory stimuli such as LPS. Very little work 
explores how IL-12 stimulation itself affects this pathway. It has been shown in 
the macrophage cell line, J774E, that IL-12 induces p38 phosphorylation, but not 
JNK or ERK1/2 (211).  Zhang et al., demonstrated that in T cells, p38 activation 
is required for IL-12 induced IFNγ production (212). However, this requirement 
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has not been established in primary macrophages, macrophage cell lines, TIMS, 
TAMs, or MDSCs.     
In this study, we hypothesize that IL-12 alters how TIMs and TAMs from 
the 4T1 mammary carcinoma respond to inflammatory stimuli. LPS is used as a 
model stimulus to demonstrate that IL-12 provides an immunological window that 
enhances the response of TIMS and TAMs to subsequent stimuli in a manner 
similar to vaccine adjuvants. Given the strong association between IL-12 and 
IFNγ immunological effects, we also focus on whether IFNγ is required for IL-12 
induced changes in TIMs in response to LPS. Because several pathways 
contribute to the inflammatory profile of myeloid cells, we also sought to identify if 
IL-12 affects common signaling pathways associated with myeloid responses to 
LPS in order to begin to understand how this proposed immunological window is 
established. We evaluated if IL-12 impacted the status of several inflammatory 
intracellular signaling molecules including mitogen activated protein kinases 
(MAPKs) after LPS stimulation of 4T1 TIMs. 
 
Materials and Methods 
 
Mice 
Wild type BALB/c and IFNγ-deficient BALB/c (C.12S7(B6)-ifngtm1Ts/J) were 
obtained from Jackson Laboratories (Bar Harbor, Maine, USA). Animals were 
maintained in the University of Louisville’s Research Resources Facility. All 
animal care and experimental procedures were performed using protocols and 
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guidelines approved by the University of Louisville Institutional Animal Care and 
Use Committee.  
 
Tumor harvesting and cell isolation 
4T1 cells were obtained from ATCC (Manassas, Virginia, USA). Tumor 
cells were maintained through in vivo passage with limited intermittent in vitro 
culture. Seven-to-eight weeks-old BALB/c or IFNγ-deficient mice were injected 
with 2x104 4T1 cells subcutaneously at the rear, left mammary fat pad. Tumors 
were harvested at approximately day 26. Tumors from WT and IFNγ-deficient 
mice were pooled for isolation of CD11b+ cells. Tumors were processed using 
Tumor Dissociation Kit and gentleMACS tissue dissociator (Miltenyi Biotec, 
Auburn, California, USA). CD11b+ cells were selected using anti-CD11b 
magnetic microbeads, LS columns and MACS magnet system  (Miltenyi Biotec, 
Auburn, California, USA). For peritoneal cell harvest, peritoneal fluid was 
obtained using a 21G1 needle and DPBS containing 2% FBS. Red blood cells 
were lysed using a balanced salt solution. Cells were depleted of CD19+ and 
CD5+ followed by positive selection of CD11b+ using LS columns and the MACS 
magnet system. Cell isolation purity was confirmed by flow cytometry and 
exceeded 95% for both tumor and peritoneal cell isolation. 
 
Reagents 
LPS (Escherichia coli serotype O11:B4) was purchased from Sigma-
Aldrich (St. Louis, Missouri, USA). Recombinant mouse IL-12 was obtained from 
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R&D Systems (Minneapolis, Minnesota, USA). Western blot detection of protein 
used the following primary antibodies: anti-phospho-p38 (Thr180/Tyr182), anti-
p38, anti-phospho-JNK/SAPK (Thr183/Tyr185), anti-JNK/SAPK, anti-phospho-
p44/42 (Thr202/Tyr204), anti-p44/42 (Cell signaling Technology, Beverly 
Massachusetts, USA) and anti-B-actin (Sigma-Aldrich, St. Louis, Missouri, USA).   
 
In vitro treatment protocol 
 For protein, CD11b+ cells were treated with 100ng/mL LPS, 100ng/mL IL-
12, or IL-12 + LPS at the same concentrations for 18 hours in RPMI with 5% fetal 
bovine serum. For IL-12 pretreatment, CD11b+ cells were treated with 100ng/mL 
IL-12 for 2 hours followed by 100ng/mL LPS for 18 hours.  For mRNA, CD11b+ 
cells were treated with 100ng/mL LPS, 100ng/mL IL-12, or IL-12 + LPS at the 
same concentrations for 2 hours in RPMI with 5% fetal bovine serum. For IL-12 
pretreatment, CD11b+ cells were treated with 100ng/mL IL-12 for 2 hours 
followed by 100ng/mL LPS for 2 hours. All incubations were done at 37˚C. 
 
Cytokine measurement 
Tumor infiltrating and peritoneal CD11b+ cells were harvested as 
described above. Following stimulation, TNFα, IL-6, and IL-10 protein levels were 
measured using the Cytometric Bead Array Mouse Inflammation Kit (BD 
Biosciences, San Jose, California, USA) according the manufacturer’s 
instructions. Analysis was performed using FACSCalibur cytometer and FCAP 
array software (BD Biosciences, San Jose, California, USA). 
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Real-time PCR analysis  
MACs One-step cDNA Kit (Miltenyi Biotech, Auburn, California, USA) was 
used for RNA and cDNA synthesis. cDNAs were amplified using a 20μL reaction 
containing SYBR green (New England Biolabs, Ipswich, Massachusetts, USA). 
QuantiTECT primers assays for mouse TNFα, IL-6, IL-10, and B-actin (Qiagen, 
Hilden, Germany) were used and PCR reactions were performed and captured 
by DNA Opticon 2 (MJ Research/Bio-rad, Hercules, California, USA). The 
relative expression software tool (REST 2009) was used to calculate relative fold 
changes among treatment groups. 
 
Western blot analysis 
Cells were lysed in buffer containing 125mM Tris (pH 6.8), 2% SDS, 20% 
glycerol, 200μM PMSF, protease inhibitor mixture (Promega, Madison, 
Wisconsin, USA), phosphatase inhibitor mixture (ThermoFisher Scientific, 
Rockford, Illinois, USA). Total protein content for each sample was assessed by 
BCA protein assay (ThermoScientific, Rockford, Illinois, USA). Equal amounts of 
protein were separated on 10% Criterion gels (Bio-rad, Hercules, California, 
USA), by SDS-PAGE. Proteins were transferred to nitrocellulose membranes 
using Trans-blot Turbo Transfer system (Bio-rad, Hercules, California, USA). 
Antibody-bound proteins were detected using an ECL western blot system (GE 
Healthcare, Pittsburgh, Pennsylvania, USA), and the membranes were exposed 
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to UltraCruz 5x7 autoradiography film (Santa Cruz Biotechnology, Santa Cruz, 
California, USA) 
 
Flow cytometry  
Single cell suspensions of WT and IFNγ-deficient CD11b+ tumor 
infiltrating cells were stained with fluorescently conjugated antibodies against 
murine CD11b, F4/80, pan Gr1, Ly6G, Ly6C (all but anti-F4/80 obtained from BD 
Biosciences, San Jose, California, USA; anti-F4/80 obtained from 
Affymetrix/eBiosciences, San Diego, California, USA) for 30 minutes at 40C, 
washed and analyzed using FACSCalibur flow cytometer and FlowJo software 
(Tree Star, Ashland, Oregon, USA).  
 
4T1 supernatant production 
Primary 4T1 cells were harvested directly from  tumor bearing animals by 
mashing the tumor mass through a 100 micron filter cup and then passage over 
a 70 micron nylon filter were plated in 10 cm dishes overnight at 107 cells/dish in 
normal RPMI 1640 with 5% FBS.  After overnight culture, tissue debris and 
stroma were removed from the plates by pipetting away the supernatant and 
replacing with fresh media.  The cell cultures were maintained at 37oC and 
5%CO2 and allowed to grow to 70% confluency.  At this point, cells were split 
and transferred for expansion. Once desired growth was achieved, supernatants 
were collected from the flasks and centrifuged at 450g for 5 minutes. The pellet 
was discarded and the clarified supernatants were then centrifuged a 2000g for 
49 
 
10 minutes.  The supernatant was then applied to a Vivacell 100kd MWCO 
concentrator (Sartorius) and centrifuged in multiple 10-15 minute spins until the 
volume of the retentate was reduced to a final volume of approximately 3-4 ml.  
The retentate was aliquotted into 500 μl amounts and stored at -20oC until use.  
Concentrated retentate was tested for endotoxin by LAL (Limulus Amebocyte 
Lystate) Test (Lonza, QCL-1000 assay).  The concentrate was also screened for 
mycoplasma using MycoAlert Assay (Lonza).    Protein concentration was 
determined by BCA (Pierce).  Optimal stimulation dose was determined by dose 
response curve and typically was 100-300 ng/ml.  Verified concentrate was then 
used to stimulate macrophages in in-vitro assays. 
 
Statistical analysis 
Statistical significance was calculated using unpaired student’s t test when 
comparing two groups. One-way ANOVA was used for statistical difference when 
analyzing greater than two groups. p<0.05 was considered to be statistically 
significant. 
Results 
IL-12 impacts the response of 4T1 tumor associated myeloid cells to LPS 
It has been reported that TIMs and TAMs from mice bearing established 
tumors are polarized towards a functional phenotype that promotes 
immunosuppression and immune evasion as well as metastasis (213, 214).  
Additionally, TIMs and TAMs have been implicated in decreasing the efficacy of 
chemotherapeutic agents (215). TIMs and TAMs express high levels of anti-
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inflammatory cytokines, IL-10 and TGFβ, and low levels of pro-inflammatory 
cytokines such as TNFα, IL-12, IFNγ, and IL-6 (213) Introduction of a priming 
molecule that would allow for a more robust TIM and TAM response to a 
subsequent pro-inflammatory stimulus could help overcome this profound 
immunosuppression and even improve the effects of chemotherapeutic agents.  
To test the hypothesis that IL-12 acts a primer and impacts the ability of 
TIMs and TAMs to respond to an inflammatory stimulus, CD11b+ cells were 
isolated from the peritoneum of 4T1 bearing BALB/c mice and from non-tumor 
bearing control BALB/c mice. These TAMs and control peritoneal myeloid cells 
were treated with IL-12 alone, LPS alone, IL-12 + LPS simultaneously for 18 
hours, or pretreated with IL-12 for 2 hours followed by LPS for 18 hours.  This 
treatment protocol allowed for examination of whether IL-12 immediately 
changed TAMs response to LPS or if there was a temporal effect seen with IL-12 
pretreatment followed by LPS treatment.  
We measured the levels of pro-inflammatory cytokines, TNFα and IL-6, 
and the anti-inflammatory cytokine, IL-10 using a cytometric bead array (CBA).  
We then compared our treatment groups in both 4T1 peritoneal TAMs (5A, D, G) 
and control peritoneal myeloid cells (Fig. 5B, E, and H). We also compared each 
treatment group between 4T1 peritoneal TAMs and control peritoneal myeloid 
cells side-by-side (Fig. 5C, F, and I).  
We found that IL-12 alone did not elicit any TNFα from either control 
peritoneal myeloid cells or 4T1 peritoneal TAMs (Fig. 5A and B). LPS alone 
significantly increased the amount of TNFα secreted by control peritoneal 
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myeloid cells and 4T1 peritoneal TAMs (Fig. 5A and B). When directly comparing 
the amount of TNFα secreted by control peritoneal myeloid cells and 4T1 
peritoneal TAMs in response to LPS, we show that there was an overall 
decrease in TNFα produced by 4T1 peritoneal TAMs, but this decrease was not 
significant (Fig. 5C). When peritoneal myeloid cells were treated with IL-12+LPS 
simultaneously, we again saw an increase in TNFα production as compared to 
untreated and IL-12 treated groups in both control peritoneal myeloid cells and 
4T1 peritoneal TAMs (Fig. 5A and B). When we directly compared, IL-12+LPS 
treatment between control peritoneal macrophages and 4T1 peritoneal TAMs, 
there was no difference in TNFα cytokine production (Fig. 5C). When control 
peritoneal myeloid cells and 4T1 peritoneal TAMs were pretreated with IL-12 
followed by LPS, we observed increased TNFα secretion over untreated and IL-
12 treated control peritoneal myeloid cells and 4T1 peritoneal TAMs. There was 
no significant difference in the amount of TNFα produced after IL-12 pretreatment 
followed by LPS when we directly compared peritoneal myeloid cells from control 
and 4T1-bearing mice (Fig. 5C). There was a significant decrease in the amount 
of TNFα produced in response to IL-12+LPS when compared to LPS alone and 
IL-12 pretreatment followed by LPS in control peritoneal myeloid cells (Fig. 5A).  
Although not statistically significant, a similar trend was noticed in 4T1 peritoneal 
TAMs. Overall, pretreatment of control peritoneal myeloid TAMs and 4T1 
peritoneal TAMs did not result in a significant increase in the amount of TNFα 
secreted in response to LPS. Simultaneously treatment of control myeloid cells 
and 4T1 peritoneal TAMs caused a decrease in the amount of TNFα produced 
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when compared to cells treated with LPS alone or IL-12 pretreatment followed by 
LPS. 
We noted that when both control peritoneal myeloid cells and 4T1 
peritoneal myeloid cells were exposed to LPS, IL-12+LPS, and IL-12 
pretreatment followed by LPS, both cells types produced significantly higher 
amounts of IL-6 as compared to untreated and IL-12 treated cells (Fig. 5D and 
E). We also observed, although not statistically significant that pretreatment of 
peritoneal myeloid cells from both control and 4T1-bearing mice with IL-12 
followed by LPS enhanced the amount of IL-6 produced as compared to LPS or 
IL-12+LPS treatment (Fig. 5A and B). When compared directly, control peritoneal 
myeloid cells and 4T1 peritoneal TAMs secreted similar amounts of IL-6 in 
response to each treatment (Fig. 5F).  
Control peritoneal myeloid cells and 4T1 peritoneal TAMs secreted similar 
amounts of IL-10 in response to LPS alone and IL-12+LPS which was a 
significant increase over cells that were untreated or treated with IL-12 alone 
(Fig. 5G and H). Interestingly, both control peritoneal myeloid cells and 4T1 
peritoneal TAMs secreted significantly less IL-10  after being pretreated with IL-
12 followed by LPS as compared to treatment with LPS alone or  IL-12+LPS (Fig. 
5G and H). When we compared each treatment group directly between control 
peritoneal myeloid cells and 4T1 peritoneal TAMs, there was a significant 
difference in the amount IL-10 produced in response to IL-12+LPS (Fig. 5I). 
Overall, pretreatment with IL-12 followed by LPS treatment of control peritoneal 
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myeloid cells and 4T1 peritoneal TAMs resulted in a significant decrease in the 
amount of IL-10 produced as compared to LPS alone and IL-12+LPS. 
 
4T1 peritoneal TAMs produce less IFNγ than control peritoneal myeloid cells in 
the presence of IL-12. 
 Because of the strong association between the immune effects of IL-12 
and IFNγ, we observed the amount of IFNγ produced by control peritoneal 
myeloid cells and 4T1 peritoneal TAMs. We wanted to determine if there was 
difference in the amount of IFNγ produced by control peritoneal myeloid cells and 
4T1 peritoneal myeloid cells.  When we looked at mRNA levels of IFNγ, we noted 
that all treatments of both control peritoneal myeloid cells significantly affected 
the level of IFNγ mRNA expression (Fig 6A and B). First, we compared the 
mRNA levels when each treatment group for control peritoneal myeloid cells and 
4T1 peritoneal TAMs was normalized to untreated cells of the same type (Fig. 
6A). We found that there was significantly more IFNγ mRNA expressed in control 
peritoneal myeloid exposed to IL-12, IL-12+LPS, and IL-12 pretreatment followed 
by LPS as compared to 4T1 peritoneal TAMs.  Secondly, we compared the IFNγ 
mRNA levels between control peritoneal myeloid cells and 4T1 peritoneal TAMs 
when all treatments for both cell types were normalized to untreated control 
peritoneal myeloid cells (Fig. 6B). We found that 4T1 peritoneal TAMs expressed 
significantly less IFNγ mRNA as compared to control peritoneal myeloid cells 
(Fig. 6B), and this observation was unchanged with the addition of IL-12 alone or 
LPS alone. The addition of IL-12 simultaneously with LPS or as pretreatment 
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before LPS significantly increased the amount of IFNγ mRNA in both control 
peritoneal myeloid cells and 4T1 peritoneal TAMs (Fig 6A). There was still, 
however, a large difference in the amount of IFNγ mRNA between control 
peritoneal myeloid cells and 4T1 peritoneal TAMs in response to IL-12+LPS and 
IL-12 pretreatment followed by LPS when untreated control peritoneal myeloid 
cells were used as the reference (Fig. 6B). 
 We also compared IFNγ cytokine produced in response to each treatment 
in control peritoneal myeloid cells and 4T1 peritoneal myeloid cells. We found 
that IL-12 alone and LPS alone resulted in a small increase in IFNγ secretion in 
both control peritoneal myeloid cells and 4T1 peritoneal TAMs, and that there 
was no difference between the two groups with either treatment. When myeloid 
cells from the peritoneum of control and 4T1-bearing mice were exposed to IL-
12+LPS and IL-12 pretreatment followed by LPS, they both secreted significantly 
more IFNγ as compared to treatment with IL-12 or LPS (Fig. 6C).  4T1 peritoneal 
TAMs secreted significantly less IFNγ in response to IL-12+LPS and IL-12 
pretreatment followed by LPS (Fig. 6C). From these data, we show that 4T1 
peritoneal TAMs express less IFNγ mRNA and cytokine levels at baseline. The 
addition of IL-12+LPS and IL-12 pretreatment followed by LPS increases the 
amount of IFNγ produced in 4T1 peritoneal TAMs, but not to the same extent as 
in control peritoneal myeloid cells. 
 
Absence of IFNγ affects the response of 4T1 TAMs to IL-12 and LPS 
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Next, we evaluated whether the absence of IFNγ would affect the 
production of TNFα, IL-6, and IL-10 by 4T1 peritoneal TAMs. 4T1 TAMs were 
isolated from the peritoneums of IFNγ-deficient mice and treated as mentioned 
above. We compared the mRNA and proteins levels of each cytokine from wild-
type and IFNγ-deficient 4T1 peritoneal TAMs. We found 4T1 peritoneal TAMs 
from IFNγ-deficient mice secreted significantly less TNFα in response to LPS, IL-
12+LPS, and IL-12 pretreatment followed by LPS as compared to wild-type 4T1 
peritoneal TAMs (Fig 7A). The level of TNFα mRNA expression was consistently 
lower in IFNγ-deficient 4T1 peritoneal TAMs than in wild-type 4T1 peritoneal 
TAMs for treatment with LPS, IL-12+LPS, and IL-12 pretreatment followed by 
LPS although this difference was only statistically significant for IL-12 
pretreatment followed by LPS (Fig. 7D). 
 Wild-type 4T1 peritoneal TAMs secreted slightly more IL-6 in response to 
LPS, IL-12+LPS, and IL-12 pretreatment followed by LPS than IFNγ-deficient 
4T1 peritoneal TAMs, but there was no significant difference in the values (Fig 
7B).  When comparing IL-6 mRNA expression between the two groups, we 
observed that IFNγ-deficient 4T1 peritoneal TAMs had increased IL-6 mRNA 
after stimulation with LPS, IL-12+LPS, and IL-12 pretreatment followed by LPS 
(Fig. 7E). 
 Finally, our data shows that IFNγ-deficient 4T1 peritoneal TAMs produced 
significantly more IL-10 in response to LPS, IL-12+LPS, and IL-12 pretreatment 
followed by LPS as compared to wild-type 4T1 peritoneal TAMs (Fig 7C).  
Additionally, IL-10 mRNA levels were higher in IFNγ-deficient 4T1 peritoneal 
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TAMs relative to wild-type 4T1 peritoneal TAMs in response to LPS, IL-12+LPS, 
and IL-12 pretreatment followed by LPS (Fig. 7F).   
It should also be noted that if the cytokines data for IFNγ-deficient 4T1 
peritoneal TAMs is observed in isolation, pretreatment with IL-12  results 
increased TNFα and IL-6 and decreased IL-10 in response to LPS as compared 
to LPS alone and IL-12 + LPS treatment (Figs. 7A-C). The pattern was retained 
in IFNγ-deficient 4T1 peritoneal TAMs mRNA expression data for IL-6 (Fig. 7E) 
and IL-10 (Fig. 7F), but lost for TNFα (Fig. 7D).  
Overall, this data demonstrates that IFNγ is important for IL-12 induced 
changes in TNFα production in response to LPS in 4T1 peritoneal TAMs.  
Conversely, our data suggests that IFNγ is not necessary for the modification of 
IL-6 gene and cytokine expression seen with IL-12 pretreatment followed by LPS, 
and may even negatively influence IL-6 production in 4T1 peritoneal TAMs. We 
also show that IFNγ is not required for decreased IL-10 production seen with IL-
12 pretreatment followed by LPS in 4T1 peritoneal TAMs, even though IFNγ-
deficient 4T1 peritoneal TAMs produced more IL-10. 
 
IL-12 modulates the response of 4T1 tumor-infiltrating myeloid cells to LPS. 
We also tested whether IL-12 impacts the ability of myeloid cells to respond to an 
inflammatory stimulus by using CD11b+ cells isolated from 4T1 tumors. These 
4T1 CD11b+ tumor infiltrating myeloid cells (4T1 TIMs) were then exposed to the 
following treatments in vitro: IL-12 alone, LPS alone, IL-12 plus LPS 
simultaneously, or IL-12 pretreatment followed by LPS. Cytokine production was 
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measured using a cytometric bead array (CBA).  We observed that IL-12 alone 
does not induce significant production of TNFα, IL-6, or IL-10 (Fig. 8A-F) or their 
respective mRNAs (Fig. 8A, C, E).  Conversely, LPS alone and IL-12 plus LPS 
given simultaneously, resulted in significant production of TNFα, IL-6, and IL-10 
(Fig. 8A, C, E) and their respective mRNAs (Fig. 8A, C, E). When 4T1 TIMs were 
pretreated with IL-12 and then exposed to LPS, we observed a significant 
increase in the protein and mRNA levels of TNFα and IL-6 as compared to 
treatment with LPS alone or IL-12 plus LPS (Fig. 8A-D). On the other hand, 
pretreatment with IL-12 followed by LPS treatment of 4T1 TIMs resulted in a 
significant decrease in the amount of IL-10 (Fig. 8E-F).  
 We also assessed if IL-12 increased the amount of IFNγ produced by 4T1 
TIMs in response to LPS. We show that IL-12 induced a significant amount of 
IFNγ mRNA and cytokine from 4T1 TIMS as compared untreated 4T1 TIMs (Fig. 
9A and B). 4T1 TIMS produced significantly more IFNγ when treated with IL-12 
+LPS or pretreated with IL-12 followed by LPS than when treated with LPS alone 
(Fig. 9A and B). 
 
IL-12 increases pro-inflammatory cytokine produced by 4T1 TIMs in response to 
4T1 tumor derived products 
 We have demonstrated that IL-12 enhances the production of pro-
inflammatory cytokines, IL-6 in 4T1 peritoneal TAMs, TNFα and IL-6 in 4T1 TIMs 
and decreases the secretion of IL-10 by 4T1 peritoneal TAMs and 4T1 TIMs in 
response to LPS. We used LPS as a model stimulus to demonstrate that IL-12 
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augments how TIMs and TAMs respond to inflammatory stimuli. It has been 
proposed that the tumor secrete products with pro-inflammatory and anti-
tumorigenic potential but because of chronic exposure to these signals, 
immunosuppression is induced leading to continued immune evasion, tumor 
growth, and metastasis (216). We investigated whether IL-12 could also augment 
the response of 4T1 TIMs to tumor derived products. We concentrated 
supernatants from ex vivo harvested 4T1 tumors, and treated 4T1 TIMs with IL-
12 or 4T1 supernatant alone, IL-12+4T1 supernatant, IL-12 pretreatment followed 
by 4T1 supernatant.  We found that treatment with 4T1 supernatant led to a small 
but significant amount of TNFα and IL-6 from 4T1 TIMs (Figs. 10A and 10B). We 
also noted the 4T1 supernatant alone caused a tremendous increase in the 
amount IL-10 secreted from 4T1 TIMs (Fig. 10C).  A major finding was that IL-12 
pretreatment led to a significant enhancement of the amount of pro-inflammatory 
cytokines, TNFα and IL-6, produced in response to 4T1 supernatants (Figs. 10A 
and B). Interestingly, treating 4T1 TIMs with IL-12+4T1 supernatants 
simultaneously or pretreating with IL-12 followed by 4T1 supernatant did affect 
the amount of IL-10 produced (Fig. 10C). Overall, this data shows that IL-12 
changes the response of 4T1 TIMs to 4T1 supernatant from predominantly IL-10 
to a phenotype that includes proinflammatory cytokines, TNFα and IL-10 in 
addition to IL-10. 
 
IL-12 modulates the response of IFNγ-deficient, 4T1 tumor-infiltrating myeloid 
cells to LPS. 
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IFNγ is well known activator of myeloid cells and IL-12 has been shown to induce 
IFNγ production by myeloid cells (217). Additionally, it has been shown that much 
of IL-12’s anti-tumor influence can be attributed to IFNγ (175, 210, 218).  
Conversely, there are studies that demonstrate that IL-12 has immune properties 
that are independent of IFNγ (219, 220).  Therefore, we sought to determine if 
IFNγ was important for our observed finding that pretreatment of 4T1 TIMs with 
IL-12 increased the amount of pro-inflammatory cytokines, TNFα and IL-6 and 
decreased anti-inflammatory cytokine, IL-10 produced in response to LPS. To 
approach this question, 4T1 TIMs were isolated from IFNγ-deficient mice and 
treated in the same manner as their wild-type counterparts.  
To determine if there were differences in the myeloid cell population of 
4T1 tumors harvested from wild-type and IFNγ-deficient mice, CD11b+ cells from 
the tumors of both animal types were analyzed using flow cytometry. The level of 
expression of myeloid cell markers Gr1, F4/80, Ly6C, and Ly6G were 
insignificant between wild-type and IFNγ-deficient 4T1 TIMs (Fig 11). 
When IFNγ-deficient 4T1 TIMs were stimulated, we found that IL-12 alone 
stimulated minimal TNFα, IL-6, and IL-10 (Fig. 12A-F).  IFNγ-deficient 4T1 TIMs 
produced similar amounts of TNFα, IL-6, and IL-10 in response to LPS and IL-12 
plus LPS (Fig. 12A, C, E). IL-12 pretreatment followed by LPS exposure caused 
a significant increase in TNFα and IL-6 cytokine production and a reciprocal 
decrease in IL-10 cytokine production by IFNγ-deficient 4T1 TIMs (Fig. 12A, C, 
E). However, no differences in gene expression were observed between LPS 
alone, IL-12 plus LPS, and IL-12 pretreatment followed by LPS in IFNγ-deficient 
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4T1 TIMs (Fig. 12B-D). Overall, the absence of IFNγ in 4T1 TIMs did not 
significantly affect the increase in TNFα and IL-6 cytokine levels and reciprocal 
decrease in IL-10 seen with IL-12 pretreatment followed by exposure to LPS. 
Conversely, there was no increase in TNFα and IL-6 gene expression and no 
decreased IL-10 gene expression seen in IFNγ-deficient 4T1 TIMs pretreated 
with IL-12 followed by LPS. This data suggest that the priming effects of IL-12 
works through various mechanisms at both the transcriptional and translational 
levels, and may have an IFNγ independent component. 
 
IFNγ partially impacts the response of 4T1 TIMs to IL-12 and LPS 
The data previously described shows cytokine and gene expression when 
comparing our various treatment groups in either wild-type 4T1 TIMs exclusively 
or IFNγ-deficient 4T1 TIMs exclusively. This data shows that even in the absence 
of IFNγ, pretreatment of 4T1 TIMs with IL-12 increases the amount of TNFα, IL-6 
cytokine produced, and decreases the amount of IL-10 cytokine produced in 
response to LPS. Conversely, we demonstrate that increased TNFα and IL-6 
gene expression and decreased IL-10 gene expression induced by IL-12 
pretreatment followed by LPS is no longer present in IFNγ-deficient 4T1 TIMs. 
These observations prompted us to directly compare each treatment group 
between wild-type and IFNγ-deficient 4T1 TIMs to more clearly understand the 
influence of IFNγ. To directly compare each treatment between WT and IFNγ-
deficient 4T1 TIMs, we reanalyzed our gene data with both wild-type and IFNγ-
deficient 4T1 TIMs mRNA levels for each gene normalized to wild-type untreated 
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4T1 TIMs. At baseline, we found that there was no difference in TNFα gene 
expression between untreated wild-type and IFNγ-deficient 4T1 TIMs (Fig. 13A). 
There was, however, a small but significant difference in IL-6 gene expression 
between untreated wild-type and IFNγ-deficient 4T1 TIMs that was not affected 
by IL-12 treatment (Fig 13B). Additionally, there was significantly less IL-10 gene 
expression in untreated IFNγ-deficient 4T1 TIMs as compared to wild-type 4T1 
TIMs (Fig. 13C). This difference in IL-10 mRNA levels between wild-type and 
IFNγ-deficient 4T1 TIMs was decreased with IL-12 treatment (Fig 13C).  We 
found that TNFα gene expression was significantly lower in the IFNγ-deficient 
4T1 TIMs as compared to wild-type 4T1 TIMs in response to LPS alone, IL-12 
plus LPS, and IL-12 pretreatment followed by LPS (Fig. 13A).   There was no 
significant difference in IL-6 gene expression between wild-type and IFNγ-
deficient 4T1 TIMs treated with LPS, IL-12 plus LPS, and IL-12 pretreatment 
followed by LPS (Fig. 13B). For IL-10 gene expression, there was no difference 
in the IL-10 gene response of wild-type and IFNγ-deficient TIMs to IL-12 
pretreatment followed by LPS, but there was a significant difference in IL-10 
gene expression between wild-type and IFNγ-deficient 4T1 TIMs in response to 
IL-12 plus LPS (Fig. 13C). Although the difference in IL-10 gene expression in 
response to LPS was not significant between wild-type and IFNγ-deficient TIMs, 
there was noticeable variance between the two TIM populations (Fig. 13C). 
To directly compare cytokine levels of wild-type and IFNγ-deficient TIMs in 
response to our treatments, we combined cytokine data from figures 1 and 2 in 
table form. When directly comparing cytokine production between wild-type and 
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IFNγ-deficient 4T1 TIMs for each treatment, we observed lower amounts of TNFα 
in IFNγ-deficient 4T1 TIMs for all treatment groups although there was only a 
significant decrease in TNFα for the IL-12 pretreatment followed by LPS group 
(Table I). There was no significant difference in IL-6 cytokine production between 
wild-type and IFNγ-deficient 4T1 TIMs for any of the treatment groups (Table I). 
Finally, although there was an overall decrease in IL-10 cytokine production in 
IFNγ-deficient 4T1 TIMs for all treatment groups, there was only a significant 
difference in the IL-12 treatment group when comparing the two populations 
(Table I).  
In summary, by directly comparing gene expression and cytokine 
production in wild-type and IFNγ 4T1 TIMs, we show that IFNγ is necessary for 
the increase in TNFα after IL-12 pretreatment followed by LPS. Conversely, our 
data demonstrate that the effect of IL-12 pretreatment on the response of 4T1 
TIMs to LPS in terms of IL-6 gene expression and cytokine production is 
independent of IFNγ. Finally, we show that IL-12 decreases the amount of IL-10 
cytokine produced, but not IL-10 gene expression by 4T1 TIMs in the absence of 
IFNγ. 
 
IL-12 alters the 4T1 TIMs activation of MAPK pathway in response to LPS 
Our data thus far has shown that IL-12 affects the response of TIMs to LPS in a 
manner that is partially independent of IFNγ. We observed the levels of TNFα, IL-
6, and IL-10 in response to IL-12 and LPS. There are many pathways involved in 
the production of these cytokines in myeloid cells in response to inflammatory 
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stimuli such as LPS including signal transducer and activator of transcription 
(STATs), NF-κβ, AP-1, and AKT (12). The MAPK signaling cascade is well-
studied and has been shown to be important in the signaling pathway of TNFα, 
IL-6, IL-10, and LPS (81, 87, 90). These same signaling pathways also trigger 
the resolution of inflammation through feedback inhibition loops that lead to 
activation of suppressor of cytokine signaling (SOCS) proteins and IL-10 
production (12). IL-12 signaling is propagated via JAK2 and STAT4 (156, 157). It 
has also been reported that IL-12 activates the MAPK pathway (161). We 
hypothesized that IL-12 may affect the activation status of one or more of these 
pathways to augment the inflammatory profile of 4T1 TIMs in response to LPS. 
Additionally, given the evidence that the MAPK pathway is involved in both IL-12 
and LPS signaling, we postulated that the MAPK pathway may be affected in 4T1 
TIMs exposed to IL-12 followed by LPS.   
First, we investigated the impact of IL-12 on several inflammatory 
signaling components. We found that IL-12 did not affect the phosphorylation 
status of NF-κβ p65 in 4T1 TIMs (Fig. 14A) In addition to this finding, we found 
no change in total amount of NF-κβ p50 in 4T1 TIMs (Fig 14A). We also looked 
at the influence of IL-12 on 4T1 TIM expression of cyclooxygenase-2 (COX-2), 
which has been shown to be important in cancer-related inflammation (89).  We 
observed no change in 4T1 TIM expression of COX-2 in response to IL-12.  We 
also noted that IL-12 did not affect the phosphorylation of GSK3β and AKT in 4T1 
TIMs (data not shown). 
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Next, we evaluated the effect of IL-12 on the MAPK pathway. For these 
experiments, we also gauged how pretreatment with IL-12 affected the MAPK 
pathway after exposure to LPS.   When wild-type 4T1 TIMs were exposed to LPS 
alone, there was phosphorylation of MAPK proteins p38, JNK, and p44/42 that 
diminished over time (Fig. 14B). Conversely, IL-12 alone elicited a very low level 
of phosphorylation of the MAPK protein p38, but no p44/42 or JNK 
phosphorylation at the observed time points (Fig. 14B).  When TIMs were 
pretreated with IL-12 for 2 hours and then exposed to LPS, there was significant 
enhancement of phosphorylation of p38, JNK, and p44/42 as compared to IL-12 
or LPS alone (Fig. 14B).  
Finally, we examined MAPK protein phosphorylation in IFNγ-deficient 4T1 
TIMs in response to IL-12 and LPS. We wanted to assess if the enhancement of 
MAPK signaling seen with IL-12 pretreatment of 4T1 TIMS was at all IFNγ 
independent. We observed that treatment of IFNγ-deficient 4T1 TIMs with LPS 
alone resulted in a similar pattern of phosphorylation of p38, JNK, and p44/42 as 
seen in wild-type 4T1 TIMs (Fig. 14C). IL-12 caused some phosphorylation of 
p38, as well as p44/42 MAPK proteins in IFNγ-deficient 4T1 TIMs (Fig. 14C).  
Finally, pretreatment of IFNγ-deficient 4T1 TIMs with IL-12 did not cause a 
notable increase in p38 and JNK phosphorylation, as seen in wild-type 4T1 TIMs 
(Fig. 14C). However, pretreatment of IL-12 followed LPS treatment did cause 
increased phosphorylation of p44/42 at an earlier time point (15 minutes) when 
compare to LPS alone (Fig. 14C).  
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Overall we demonstrate that IL-12 does not impact activation or 
expression of NF-κβ in 4T1 TIMs. Additionally, the pro-inflammatory enzyme, 
COX-2 was not affected by IL-12 treatment of 4T1 TIMs. We do show that IL-12 
enhances the phosphorylation of MAPK proteins after LPS stimulation in 4T1 
TIMs. Our data suggests that the enhanced phosphorylation of p38 and JNK is 
dependent on IFNγ as this enhancement was lost when IFNγ-deficient 4T1 TIMs 
were pretreated with IL-12 followed by LPS. We did, however, identify that in the 
absence of IFNγ, IL-12 enhances the phosphorylation of p44/42 in response to 
LPS in 4T1 TIMs at an earlier time point. 
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Discussion 
Myeloid-derived cells are remarkably dynamic and display an array of 
functions and activities. The dynamic nature of myeloid cells is especially evident 
in cancer. Myeloid cells in cancer have the ability to initiate and promote tumor 
growth, as well as suppress their own and other cell types’ capability to thwart 
cancer progression which provides an opportunity for targeting these cells in anti-
cancer therapies.  Many have sought ways to exploit the functional plasticity of 
myeloid cells in cancer in order to aid in eradicating established tumors. Recent 
approaches that have been shown to modulate the functional phenotype of TAMs 
and TIMs and improve anti-tumor immunity include engagement and activation of 
TAMs and TIMs via TLR4 (221), local low-dose irradiation (222), and 
administration of biological nanoparticles combined with chemotherapeutic 
agents (223). IL-12 can activate both the innate and adaptive arms of the 
immune system and much effort has been used to investigate its effectiveness as 
an anti-tumor agent and therapeutic vaccine adjuvant. In this study, we explore 
how IL-12 impacts the tumor associated and tumor infiltrating myeloid cell’s 
response to the inflammatory stimulus, LPS, as well as tumor derived products. 
We use LPS solely as a model inflammatory stimulus to demonstrate that IL-12 
produces an immunological window in which TAMs and TIMs are more able to 
respond to subsequent pro-inflammatory and anti-tumor signals. Interestingly, it 
has been shown that ex-vivo treatment with LPS of tumor-associated 
macrophages from the ascites and blood of ovarian cancer patients leads to 
enhances activation and tumor cell cytoxicity of NK cells (221). 
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Our data show that IL-12 enhances the amount of TNFα and IL-6 and 
decreases the amount of IL-10 4T1 TIMs secrete in response to LPS (Fig. 8). 
This result  aligns with data using TIMs from the 3LLC lung cancer (180). An 
important distinction in this study include showing that exposure of TIMs for only 
2 hours versus overnight pre-culture with IL-12 conferred a similar cytokine 
response to LPS in vitro. Additionally, treating TIMs with IL-12 and LPS 
simultaneously did not impact the cytokine and mRNA levels to the degree that 
pre-treatment with IL-12 followed by LPS treatment. This observation suggests 
that although IL-12 does not induce the production of cytokines and mRNA 
measured in TIMs, it does initiate a temporal and internal change in myeloid cells 
that alters its response to subsequent stimuli. 
In 4T1 peritoneal TAMs, adding IL-12 simultaneously with LPS led to a 
slight decrease in TNFα secretion (Fig. 5B). This difference was no longer 
present when 4T1 peritoneal TAMs were pretreated with IL-12 followed by LPS 
(Fig 5B). We saw an increase in IL-6 cytokines levels when 4T1 TAMs were 
pretreated  with IL-12 then LPS as compared to LPS alone or IL-12+LPS (Fig. 
5E). Overall, IL-12 had no significant impact on the amount TNFα and IL-12 
secreted by 4T1 peritoneal TAMs in response to LPS.   
Much of IL-12’s impact on myeloid cells has been attributed to its 
elicitation of IFNγ which further stimulates myeloid cells in an autocrine fashion 
and activates NK cells and T cells in a paracrine fashion. Macrophages have 
been shown to produce nitric oxide and upregulate surface molecules associated 
with antigen presentation in response to IL-12 (169). Both of these effects are 
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dependent on IFNγ as this phenotype is erased in IFNγ-/- mice (170, 224). 
Additionally, IL-12 has been demonstrated to prime macrophages to produce 
copious amounts of NO in response to LPS (225).  
In this study, we demonstrate that IFNγ is important for the IL-12 induced 
increase in TNFα from 4T1 TIMs and 4T1 peritoneal TAMs in response to LPS. 
(Fig. 13A, Table I, Fig 7A and B). It has been previously shown that IFNγ 
potentiates the cytoplasmic accumulation of TNFα mRNA (226). It has also been 
reported that activated monocytes regulate TNFα gene expression both 
transcriptionally and post-transcriptionally in response to IFNγ (227). A more 
recent publication showed that IFNγ induced TNFα transcription via transcription 
factors, IRF-1, IRF-8, and Pu.1 (228). Our data illustrates that 4T1 TIMs from 
IFNγ-deficient mice produced significantly less TNFα mRNA and protein in 
response to IL-12 and LPS as compared to wild-type 4T1 TIMs (Fig. 13A) 
suggesting that the transcriptionally-controlled component of TNFα gene 
expression in 4T1 TIMs is dependent on IFNγ. Interestingly, although the mRNA 
levels of TNFα were significantly impacted by the absence of IFNγ, pretreatment 
of 4T1 TIMs from both wild-type and IFNγ-deficient 4T1 TIMs with IL-12 followed 
by LPS resulted in a significant increase in TNFα cytokine levels (Fig. 8A, 12A). 
This presents the possibility that post-transcriptional control of TNFα gene 
expression in 4T1 TIMs may be IFNγ independent because even in the absence 
of IFNγ, IL-12 pretreatment of TIMs led to a significant increase in TNFα cytokine 
production. 
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Our results show that there was a small but significant difference in the 
amount of IL-6 gene expression between wild-type and IFNγ-deficient 4T1 TIMs 
that was not affected by the addition of IL-12 alone (Fig. 13B). We also found that 
IL-6 gene expression and cytokine production was not significantly different 
between wild-type and IFNγ-deficient 4T1 TIMs for any of the treatment groups 
(Fig 13B, Table I). This suggests that enhancement of IL-6 gene and cytokine 
expression seen in 4T1 TIMs pretreated with IL-12 followed by LPS is 
independent of IFNγ. In 4T1 peritoneal TAMs, the absences of IFNγ did not 
significant impact on the amount IL-6 cytokine produced in response IL-12 and 
LPS (Fig. 7B). There was, however, a significant increase in IL-6 gene 
expression in IFNγ deficient 4T1 peritoneal TAMs in response to LPS, IL-
12+LPS, and IL-12 pretreatment followed by LPS when compared to WT 4T1 
periotneal TAMs (Fig. 7E). IL-6 is a cytokine with a wide variety of cellular effects 
and has been implicated in a number of pathological states including cancer. 
Gene expression of IL-6 is controlled by a number of transcriptional factors, 
including NF-κβ, C/EβP, AP-1, and Notch signaling proteins (229, 230). Studies 
have shown that IFNγ enhances the amount of IL-6 secreted in response to LPS 
in various types of cells (231, 232). Our study shows that IL-12 also increases 
the amount of IL-6 secreted by 4T1 TIMs in response to LPS in a manner that is 
independent of IFNγ. This is an important demonstration that IL-12 has a pro-
inflammatory impact on TIMs that is not dependent on IFNγ. 
We also examined the effect of treatment with IL-12 and LPS on the 
amount of the anti-inflammatory cytokine, IL-10 secreted from WT 4T1 TIMs and 
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peritoneal TAMs and IFNγ-deficient 4T1 TIMs and peritoneal TAMs. In our 
studies, IL-10 cytokine secretion was decreased when 4T1 TIMs from both WT 
and IFNγ-deficient animals were treated with IL-12 prior to exposure to LPS 
(Figs. 8E, 12E). We show that there is an overall diminution in the amount of IL-
10 secreted by IFNγ-deficient 4T1 TIMs in response to IL-12 and LPS. Our data 
also demonstrate, however, that the absence of IFNγ did not cause a difference 
in the amount of IL-10 secreted in any treatment group except for IL-12 alone 
that was statistically significant when directly comparing WT and IFNγ-deficient 
4T1 TIMs (Table I).  The amount of IL-10 secreted from TIMs in response to IL-
12 was decreased significantly in the absence of IFNγ, although the amount of 
IL-10 was very low in both groups (Table I).  We also observed that pretreatment 
of 4T1 peritoneal TAMs with IL-12 followed by LPS led to a sharp decrease in the 
amount of IL-10 as compared to LPS alone and IL-12+LPS (Fig 5H). 
It is clear from our data that IFNγ is an important factor in IL-10 gene 
expression after IL-12 and LPS treatment. When comparing wild-type and IFNγ-
deficient 4T1 TIMs directly, there were significant differences in the amount of IL-
10 gene expressed in the untreated group and the IL-12 plus LPS group (Fig. 
4C). Additionally, there was a difference in IL-10 gene expression in wild-type 
and IFNγ-deficient 4T1 TIMs in response to LPS alone although it did not reach 
statistical significance (Fig 4C).  We found that IFNγ deficient 4T1 peritoneal 
TAMs secreted higher amounts of IL-10 and had significantly increased IL-10 
gene expression when treated with IL-12 and LPS compared to WT 4T1 
peritoneal TAMS (Fig. 7C and F). It has been demonstrated that IL-10 production 
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is controlled both transcriptionally and post-transcriptionally in manner similar to 
TNFα by a number of transcription factors, microRNAs, and signaling molecules 
(233, 234). IFNγ can block IL-10 production through the PI3-kinase-GSK3β-AKT 
pathway (80). Our results show that even in the absence of IFNγ, IL-12 
decreases the amount of IL-10 produced in response to LPS and may affect the 
post-transcriptional handling of IL-10 in an IFNγ-independent manner. The 
decreased amount of IL-10 in response to LPS after IL-12 pretreatment may be 
important in the maintenance or prolongation of IL-12 induced pro-immunological 
window. 
Untreated WT and IFNγ deficient 4T1 TIMs and peritoneal TAMs did not 
express high levels of IL-10 cytokine that is classically associated with the TIM 
M2-like phenotype. This observation could be explained by the timing of the 
measurements of cytokine levels of the untreated group, which was done after 
overnight incubation. It is reasonable to expect that TIMs lysed immediately after 
harvest and selection, the IL-10 data may have been different. Several published 
reports have shown data using TIMs and TAMs from 4T1 and 3LLC tumors with 
very low levels of IL-10 cytokine expression (180, 235-237).  It is hard to 
determine from in vitro results what would be a functional or physiological 
relevant amount of IL-10 in vivo. Even so, our data clearly shows that 
pretreatment of TIMs and TAMs with IL-12 significantly decreases the amount of 
IL-10 produced in response to the inflammatory stimulus, LPS regardless of the 
presence of IFNγ. This suggests that IL-12 may prolong the action of other 
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inflammatory mediators by diminishing the reflexive production the anti-
inflammatory cytokine, IL-10. 
We expected that IL-12 would confer similar effects on the cytokine profile 
of 4T1 TIMs and peritoneal TAMs. We found that although there were some 
similarities in their response to IL-12 and LPS (i.e. decreased IL-10 after IL-12 
pretreatment followed by LPS as compared to LPS alone and IL-12+LPS and 
IFNγ not required for IL-6 cytokine increases with IL-12 pretreatment), the overall 
picture was not exactly the same for both TIMs and TAMs. When thinking about 
possibilities for these differences, two factors come to the forefront. First, all of 
our experiments were at one set time point (2 hours for mRNA and 18 hours for 
cytokine data both with 2 hour IL-12 pretreatments). It is possible that this 
timepoint was optimal for capturing the observation that supported our stated 
hypothesis for 4T1 TIMs, but was suboptimal for observing similar data in 4T1 
peritoneal TAMs. The second factor that may have contributed to differences in 
the cytokine profile between 4T1 TIMs and 4T1 peritoneal TAMs is the makeup 
of the myeloid population each group. These pooled samples of CD11b+ cells 
were not sorted to separate F4/80+ macrophages from Gr1+ monocytic and 
granulocytic MDSCs or other myeloid cells. We did some simple flow analysis of 
each group and there were some differences in percentages of different types of 
cells (data not shown), but a more in depth analysis of the myeloid cell 
populations of each group of cells would provide more information and might help 
decipher why there were differences in the response to our stimuli. 
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We also examined how IL-12 affected the cytokine profile of 4T1 TIMS 
exposed to tumor derived products. We saw that IL-12 pretreatment significantly 
enhanced the amount TNFα and IL-6 produced by 4T1 TIMs in response to 4T1 
supernatant. IL-12 pretreatment did not affect the high levels of IL-10 secreted 
from 4T1 TIMs. Assays to determine if myeloid cells pretreated with IL-12 
followed by tumor-derived products expressed higher levels of antigen 
presentation machinery or promoted the activation of T cells would be an 
interesting follow up experiment. Additionally, determining if IFNγ were necessary 
for this observation would be an interesting question to pursue. Importantly, this 
result shows that IL-12 does affect how myeloid cells respond subsequent 
stimulate and that the tumor microenvironment contains factors with inflammatory 
potential. 
Finally, we examined how several intracellular signaling pathways, 
including the MAPK pathway, were affected by our treatment of 4T1 TIMs from 
wild-type and IFNγ-deficient mice with IL-12 and LPS. There is extensive 
research describing the role of the MAPKs in LPS signaling in macrophages and 
other myeloid cells (20, 90, 238).  Most of the published data concerning IL-12 
and the MAPK pathway addresses the pathway’s involvement in IL-12 synthesis 
in response to inflammatory stimuli such as LPS. Very little work explores how IL-
12 stimulation itself affects this pathway. It has been shown in the macrophage 
cell line, J774E, that IL-12 induces p38 and p44/42 phosphorylation (211). Zhang 
et al., demonstrated that in T cells, p38 activation is required for IL-12 induced 
IFNγ production (212). However, this requirement has not been established in 
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primary macrophages, macrophage cell lines, TIMS, TAMs, or MDSCs. We 
found that IL-12 alone only induced minimal phosphorylation of the MAPKs wild-
type and IFNγ-deficient 4T1 TIMs (Fig. 14). We also observed, as expected, that 
LPS alone induced phosphorylation of the MAPK pathway in 4T1 TIMs (Fig. 14). 
Phosphorylation of the MAPK pathway by LPS in 4T1 TIMs was not impacted by 
the absence of IFNγ (Fig 14). A major observation from these studies is that the 
increase in MAPK phosphorylation in response to LPS after IL-12 pre-treatment 
in wild-type 4T1 TIMs was lost in IFNγ-deficient 4T1 TIMs (Fig. 14). Importantly, 
however, in the IFNγ-deficient 4T1 TIMs, IL-12 pretreatment followed by LPS 
caused increased phosphorylation of p44/42 at an earlier timepoint when 
compared to LPS alone (Fig. 14).  The early activation of p44/42 in IFNγ-deficient 
4T1 TIMs may also contribute to the increases in TNFα and IL-6 with IL-12 
pretreatment followed by LPS even in the absence of IFNγ although it would not 
fully explain the decrease of IL-10 with that same treatment as increased 
p44/p42 is associated with increased IL-10 expression. 
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 Figure 5
 
Figure 5. IL-12 modulates the response of 4T1 peritoneal tumor associated 
myeloid cells to inflammatory stimulus, LPS. CD5-/CD19-/CD11b+ cells 
isolated from peritoneum of BALB/cJ mice with (4T1 TAMs) or without (control) 
implanted 4T1 tumors were treated with IL-12, LPS, or IL-12 and LPS for 18 
hours, pretreated with IL-12 for 2 hours and then treated with LPS for 18 hours, 
or left untreated. 100ng/mL of IL-12 and 100ng/mL of LPS were used in all 
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experiments. TNFα (A, B, C), IL-6 (D, E, F), and IL-10 (G, H, I) protein levels 
were measured using cytokine bead array.  C, F, and I, shows direct comparison 
between control and 4T1 peritoneal CD5-/CD19-/CD11b+ for each treatment. 
Figures shown represent the mean ± SEM of triplicate data and are 
representative of at least three independent experiments with similar results. (*p 
<0.05, **p<0.001) 
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Figure 6 
 
 
Figure 6. 4T1 peritoneal TAMs produce less IFNγ than control peritoneal 
myeloid cells in the presence of IL-12.  For A and B, CD5-/CD19-/CD11b+ cells 
isolated from peritoneum of BALB/cJ mice with (4T1 TAMs) or without (control) 
implanted 4T1 tumors were treated with IL-12, LPS, or IL-12+ LPS for 2 hours, 
pretreated with IL-12 for 2 hours and then treated with LPS for 2 hours, or left 
untreated.  Gene expression was determined by measuring the mRNA levels of 
IFNγ.  In A, control treatment groups are normalized to control untreated 
peritoneal myeloid cells, while 4T1 treatment groups are normalized to 4T1 
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untreated TAMs. In B, both control and 4T1 treatments groups are normalized to 
control untreated peritoneal myeloid cells. For C, CD5-/CD19-/CD11b+ cells 
isolated from peritoneum of BALB/cJ mice with (4T1 TAMs) or without (control) 
implanted 4T1 tumors were treated with IL-12, LPS, or IL-12 and LPS for 18 
hours, pretreated with IL-12 for 2 hours and then treated with LPS for 18 hours, 
or left untreated. 100ng/mL of IL-12 and 100ng/mL of LPS were used in all 
experiments. IFNγ protein levels were measured using cytokine bead array. 
Figures shown represent the mean ± SEM of triplicate data and are 
representative of at least three independent experiments with similar results. (*p 
<0.05, **p<0.001) 
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Figure 7 
 
 
Figure 7. The absence of IFNγ affects the response of 4T1 TAMs to IL-12 
and LPS. For A, B, and C, CD5-/CD19-/CD11b+ cells isolated from the 
peritoneum of wild-type and IFNγ-deficient  BALB/cJ mice with 4T1 tumors were 
treated with IL-12, LPS, or IL-12 and LPS for 18 hours, pretreated with IL-12 for 2 
hours and then treated with LPS for 18 hours, or left untreated. 100ng/mL of IL-
12 and 100ng/mL of LPS were used in all experiments.  Cytokine levels were 
measured using cytokine bead array. For D, E. and F, CD5-/CD19-/CD11b+ cells 
isolated from the peritoneum of wild-type and IFNγ-deficient  BALB/cJ mice with 
4T1 tumors were treated with IL-12, LPS, or IL-12+ LPS for 2 hours, pretreated 
with IL-12 for 2 hours and then treated with LPS for 2 hours, or left untreated.  
Gene expression was determined by measuring the mRNA levels of each TNFα, 
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IL-6, and IL-10.  All mRNA data shown was normalized to untreated wild-type 
4T1 TAMs. Figures shown represent the mean ± SEM of triplicate data and are 
representative of at least three independent experiments with similar results. (*p 
<0.05, **p<0.001) 
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Figure 8 
 
Figure 8. IL-12 modulates the response of 4T1 tumor-infiltrating myeloid 
cells to inflammatory stimulus, LPS.  CD11b+ cells isolated from 4T1 tumors of 
BALB/cJ mice were treated with IL-12, LPS, or IL-12 and LPS for 18 hours, 
pretreated with IL-12 for 2 hours and then treated with LPS for 18 hours, or left 
untreated. 100ng/mL of IL-12 and 100ng/mL of LPS were used in all 
experiments. TNFα (A), IL-6 (B), and IL-10 (C) protein levels were measured 
using cytokine bead array. For B, D, E, CD11b+ cells were isolated from 4T1 
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tumors of BALB/cJ mice and treated with IL-12, LPS, or IL-12+ LPS for 2 hours, 
pretreated with IL-12 for 2 hours and then treated with LPS for 2 hours, or left 
untreated.  Gene expression was determined by measuring the mRNA levels of 
TNFα, IL-6, and IL-10 and normalizing to untreated 4T1 CD11b+ cells. Figures 
shown represent the mean ± SEM of triplicate data and are representative of at 
least three independent experiments with similar results. (*p <0.05, **p<0.001)
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Figure 9 
 
Figure 9.  4T1 TIMs produce IFNγ in response to IL-12 and LPS. On left, 
CD11b+ cells isolated from 4T1 tumors of BALB/cJ mice were treated with IL-12, 
LPS, or IL-12+ LPS for 2 hours, pretreated with IL-12 for 2 hours and then 
treated with LPS for 2 hours, or left untreated.  Gene expression was determined 
by measuring the mRNA levels of IFNγ.  All treatment groups are normalized to 
untreated 4T1 TIMs. On CD11b+ cells isolated from 4T1 tumors of BALB/cJ mice 
were treated with IL-12, LPS, or IL-12 and LPS for 18 hours, pretreated with IL-
12 for 2 hours and then treated with LPS for 18 hours, or left untreated. 
100ng/mL of IL-12 and 100ng/mL of LPS were used in all experiments. IFNγ 
protein levels were measured using cytokine bead array. Figures shown 
represent the mean ± SEM of triplicate data and are representative of at least 
three independent experiments with similar results. (*p <0.05, **p<0.001) 
 
84 
 
Figure 10 
 
Figure 10. IL-12 increases pro-inflammatory cytokines produced by 4T1 
TIMs in response to 4T1 supernatant.  CD11b+ cells isolated from 4T1 tumors 
of BALB/cJ mice were treated with IL-12, LPS, or IL-12 and 4T1 supernatant for 
18 hours, pretreated with IL-12 for 2 hours and then treated with 4T1 supernatant 
for 18 hours, or left untreated. 100ng/mL of IL-12 was used in all experiments. 
TNFα (A), IL-6 (B), and IL-10 (C) protein levels were measured using cytokine 
bead array. Figures shown represent the mean ± SEM of triplicate data and are 
representative of at least two independent experiments with similar results. (*p 
<0.05, **p<0.001)
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Figure 11 
 
Figure 11. Innate immune cells isolated from WT and IFNγ-deficient 4T1 
tumor have similar myeloid associated surface markers. Unstimulated 
CD11b+ cells (A) isolated from 4T1 tumors of WT and Ifng deficient BALB/cJ 
mice at day 26 were stained with anti-Gr1 (B), anti-F4/80 (C), anti-Ly6C (D), and 
anti-Ly6G (E). Histograms show fluorescence of each of stained surface marker. 
Mean fluorescence intensity of surface stain for each group is stated numerically 
in parenthesis. Curves to the far left of the histogram represent isotype control for 
WT and IFNγ-deficient samples (as labeled in A). Data shown are representative 
of 3 independent experiments with similar results. 
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Figure 12 
 
Figure 12. IL-12 modulates the response of IFNγ-deficient, 4T1 tumor-
infiltrating myeloid cells to inflammatory stimulus, LPS. CD11b+ cells 
isolated from 4T1 tumors of Ifng deficient BALB/cJ mice were treated with IL-12, 
LPS, or IL-12 and LPS for 18 hours, pretreated with IL-12 for 2 hours and then 
treated with LPS for 18 hours, or left untreated. 100ng/mL of IL-12 and 100ng/mL 
of LPS were used in all experiments. TNFα (A), IL-6 (B), and IL-10 (C) protein 
levels were measured using cytokine bead array. For B, D, E, CD11b+ cells were 
isolated from 4T1 tumors of Ifng deficient BALB/cJ mice and treated with IL-12, 
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LPS, or IL-12+ LPS for 2 hours, pretreated with IL-12 for 2 hours and then 
treated with LPS for 2 hours, or left untreated.  Gene expression was determined 
by measuring the mRNA levels of TNFα, IL-6, and IL-10 and normalizing to 
bactin untreated IFNγ-deficient 4T1 CD11b+ cells. Figures shown represent the 
mean ± SEM of triplicate data and are representative of at least three 
independent experiments with similar results. (*p <0.05, **p<0.001)
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Figure 13 
 
Figure 13. IFNγ partially impacts the inflammatory gene profile of 4T1 
tumor-infiltrating myeloid cells to IL-12 and LPS.  CD11b+ cells were isolated 
from 4T1 tumors of BALB/cJ mice and Ifng deficient BALB/cJ mice and treated 
with IL-12, LPS, or IL-12+ LPS for 2 hours, pretreated with IL-12 for 2 hours and 
then treated with LPS for 2 hours, or left untreated. 100ng/mL of IL-12 and 
100ng/mL of LPS were used in all experiments. Gene expression was 
determined by measuring the mRNA levels of TNFα, IL-6, and IL-10. mRNA fold 
change averages for each gene were normalized to WT untreated tumor-
infiltrating myeloid cells for each treatment.  Figures shown represent the mean ± 
SD of triplicate data and are representative of at least three independent 
experiments with similar results. (*p <0.05, **p<0.001) 
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Table I 
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Table I. IFNγ partially impacts the cytokine response of 4T1 tumor-
infiltrating myeloid cells to IL-12 and LPS.  CD11b+ cells isolated from 4T1 
tumors of BALB/cJ mice and Ifng deficient BALB/cJ mice were treated with IL-12, 
LPS, or IL-12 and LPS for 18 hours, pretreated with IL-12 for 2 hours and then 
treated with LPS for 18 hours, or left untreated. 100ng/mL of IL-12 and 100ng/mL 
of LPS were used in all experiments. TNFα, IL-6, and IL-10 protein levels were 
measured using cytokine bead array. Average cytokine secretion for each 
treatment is compared between WT and IFNγ-deficient tumor infiltrating myeloid 
cells. Figures shown represent the mean ± SD of triplicate data and are 
representative of at least three independent experiments with similar result.
91 
 
Figure 14 
 
Figure 14. IL-12 enhances 4T1 tumor-infiltrating myeloid cell activation of 
MAPK pathway in response to LPS. (A) CD11b+ cells isolated from 4T1 tumors 
of wild-type BALB/cJ mice were treated with 100ng/mL IL-12 for the indicated 
time points. After cell lysis, Western blot was performed using antibodies against 
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phospho NF-κβ p65 (Ser536), NF-κβ p65, COX-2, NF-κβ p50, and B-actin. 
CD11b+ cells isolated from 4T1 tumors of wild-type (B) and IFNγ-deficient (C) 
BALB/cJ mice were treated with IL-12, LPS, or IL-12 and LPS, pretreated with IL-
12 for 2 hours and then treated with LPS, or left untreated for indicated time 
points. 100ng/mL of IL-12 and 100ng/mL of LPS were used in all experiments. 
After cell lysis, Western blot was performed using antibodies against phospho-
p38 (Thr180/Tyr182), total p38, phospho-JNK/SAPK (Thr183/Tyr185), total 
JNK/SAPK, phospho-p44/42 (Thr202/Tyr204), total p44/42, and B-actin. Data 
shown are representative of 3 independent experiments with similar results.
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CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTION 
  
This work contributes to our knowledge of how IL-12 impacts myeloid cells 
from the cancer environment. It also demonstrates that IL-12 has IFNγ 
independent effects on myeloid cells from tumor-bearing animals specifically with 
regards to IL-6 and IL-10.  The relationship between IL-6 and IL-10 is very 
complicated and interesting. Our data suggests that IL-12, independent of IFNγ, 
shifts the response to LPS in TIMs and TAMs to more IL-6 and less IL-10. We 
also show that IL-12 causes increased IL-6 without changes in IL-10 from TIMs in 
response to tumor derived products. Experiments to determine how IL-12 
controls the expression of IL-6 and IL-10 could lead to a better understanding of 
how these two cytokines contribute to the functional phenotype of myeloid cells. 
One of the larger hurdles of cancer immunotherapy is the strong 
immunosuppression seen in advanced cancer. Early stage cancer are usually 
easily treated and/or resected, but it is the larger and disseminated tumors that 
cause the most morbidity and mortality. Agents that combat this profound 
immunosuppression are attractive immunotherapeutic candidates. IL-12 is a very 
common immunotherapeutic agent used in clinical trials. Given the broad interest 
in its anti-cancer effects, it is vital that there is research that focuses on the effect 
IL-12 on all aspects of the immune system. An area of focus for future work might 
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include in vivo experiments to determine how myeloid cells within tumors 
respond to IL-12 in the presence and absence of IFNγ. We know that IFNγ is 
crucial for IL-12 induced tumor regression (175). This study also showed the IL-
12 binds to myeloid populations within the cancer to enhance the effects of 
adoptively transferred cytotoxic T lymphocytes partly independent of IFNγ. In vivo 
and ex vivo experiments that observe intrinsic changes in TIMs in response to IL-
12 would be helpful in determining the direct impact of IL-12 on TIMs and how 
that is related to its anti-tumorigenic effects. Our work also shows that IL-12 has 
IFNγ independent modulatory activity on tumor infiltrating myeloid cells. Our work 
and the Kerkar paper (175) illustrate the need for more in depth studies on how 
IL-12 impact TIMs and TAMs to improve cancer immunotherapy. Deciphering 
IFNγ-independent effects of IL-12 on myeloid cells within cancer may provide 
new information on how to harness the plasticity of these cells to decrease the 
immunosuppression that helps maintain cancer.   
One of the most interesting aspects of this dissertation is that IL-12 
decreased the amount IL-10 secreted in response to LPS in both 4T1 TIMS and 
peritoneal TAMs. This provides a clue to a possible mechanism by which IL-12 
provides a window for an inflammatory stimulus to be more effective. 
Inflammation is a usually a tightly controlled physiological process where 
resolution and immunosuppression are important in preventing pathology. In 
cancer, however, there is pathologic immunosuppression. IL-12 seems to break 
this immunosuppression and provide a window for other pro-inflammatory 
stimulus to be more effective. This may be due to direct effects of IL-12 on 
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myeloid cell IL-10 regulation. Our lab is currently interested in how IL-10 is 
regulated in macrophages and myeloid cells. Our data show that AMPK is a very 
important regulator of myeloid cell function and plays a large role in IL-10 
production (239, 240). Work that examines the role of IL-12 on IL-10 and AMPK 
in TIMs may provide critical answers about IL-10 induced immunosuppression 
and the role of IL-12 in reversing it. Our results are even interesting given work 
showing that IL-10 has proinflammatory effects in cancer via activation of CD8+ T 
cells (241, 242). These results reiterate the complexities of immune system 
alone, as well as, in context cancer. Understanding the multifaceted role of IL-10 
in cancer is important in harnessing the power of the immune system to combat 
cancer. 
Research always begets more questions. This work presented here is no 
exception. Some of these new questions might include: What other signaling 
pathways are impacted by IL-12 in TIMs? Is the MAPK pathway in TIMs directly 
involved and necessary for IL-12 induced tumor regression? Are epigenetic 
changes induced in TIMs after exposure to IL-12 and does this impact the 
functional phenotype of TIMs?  Does IL-12 interaction with the tumor impact the 
functional phenotype of TIMs? In conclusion, this work provides a small, but 
important piece of the puzzle as to why and how IL-12 impacts TIMs and TAMs 
and helps explain its anti-tumorigenic and pro-inflammatory potential. 
At the start of this project, although there was great research being done 
in cancer immunology and immunotherapy, there was also great skepticism 
about how much cancer immunology and immunotherapy would ultimately 
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impact cancer patients. The naming of cancer immunotherapy as Science’s 
Breakthrough of the Year for 2013 is proof that investigating the role of the 
immune system in cancer is a worthwhile pursuit.  And while the work done for 
this project is several large steps removed from clinical application, it is the 
asking of simple scientific questions like those proposed in this project that lead 
to cancer immunotherapy being named Science’s 2013 Breakthrough of the Year 
and hopefully to the ultimate goal of eradicating cancer. 
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